Lung cancers: tissue, physiology, and treatment decisions

1. A. Reduced sodium-potassium-chloride transport in the thick ascending limb (Why this does not fit)

   Loop transport inhibition weakens the medullary concentrating gradient and promotes salt and water excretion. It does not explain persistent antidiuresis with concentrated urine in this euvolemic patient.

   Reasoning steps for option A

   1. What does reduced loop sodium transport do to the concentrating gradient? Apply that prediction to lung-cancers-01, option A: Reduced sodium-potassium-chloride transport in the thick ascending limb.

      Loop transport inhibition weakens the medullary concentrating gradient and promotes salt and water excretion. For lung-cancers-01 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-01 option A, which supplied finding most strongly supports or refutes Reduced sodium-potassium-chloride transport in the thick ascending limb?

      It does not explain persistent antidiuresis with concentrated urine in this euvolemic patient. Thus, in lung-cancers-01 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Reduced aquaporin-2 insertion in collecting-duct principal cells (Why this does not fit)

   Reducing apical aquaporin-2 permits greater water excretion and more dilute urine. That is the expected response to hypotonic blood, but this patient's urine remains inappropriately concentrated.

   Reasoning steps for option B

   1. What happens to water excretion when fewer apical water channels are present? Apply that prediction to lung-cancers-01, option B: Reduced aquaporin-2 insertion in collecting-duct principal cells.

      Reducing apical aquaporin-2 permits greater water excretion and more dilute urine. For lung-cancers-01 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-01 option B, which supplied finding most strongly supports or refutes Reduced aquaporin-2 insertion in collecting-duct principal cells?

      That is the expected response to hypotonic blood, but this patient's urine remains inappropriately concentrated. Thus, in lung-cancers-01 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Increased aquaporin-2 insertion in collecting-duct principal cells (Best answer)

   Ectopic ADH can maintain V2-receptor signaling despite hypotonic plasma, increasing apical aquaporin-2 and water reabsorption. Retained water dilutes plasma sodium while the urine remains concentrated; the exclusion of renal, thyroid, adrenal, and diuretic causes supports inappropriate antidiuresis.

   Reasoning steps for option C

   1. How does persistent V2 signaling affect apical aquaporin-2? Apply that prediction to lung-cancers-01, option C: Increased aquaporin-2 insertion in collecting-duct principal cells.

      Ectopic ADH can maintain V2-receptor signaling despite hypotonic plasma, increasing apical aquaporin-2 and water reabsorption. For lung-cancers-01 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-01 option C, which supplied finding most strongly supports or refutes Increased aquaporin-2 insertion in collecting-duct principal cells?

      Retained water dilutes plasma sodium while the urine remains concentrated; the exclusion of renal, thyroid, adrenal, and diuretic causes supports inappropriate antidiuresis. Thus, in lung-cancers-01 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Increased proximal tubular bicarbonate secretion (Why this does not fit)

   Loss of bicarbonate primarily causes a normal-anion-gap metabolic acidosis. It does not account for the paired hypotonic plasma and concentrated urine that identify the water-handling problem here.

   Reasoning steps for option D

   1. What acid-base effect would proximal bicarbonate loss produce? Apply that prediction to lung-cancers-01, option D: Increased proximal tubular bicarbonate secretion.

      Loss of bicarbonate primarily causes a normal-anion-gap metabolic acidosis. For lung-cancers-01 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-01 option D, which supplied finding most strongly supports or refutes Increased proximal tubular bicarbonate secretion?

      It does not account for the paired hypotonic plasma and concentrated urine that identify the water-handling problem here. Thus, in lung-cancers-01 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Reduced aldosterone-dependent distal sodium reabsorption (Why this does not fit)

   Mineralocorticoid deficiency can cause sodium loss with hypotension and hyperkalemia. Normal adrenal function, clinical euvolemia, and the supplied urine pattern instead support ADH-mediated water retention.

   Reasoning steps for option E

   1. What pattern can mineralocorticoid deficiency produce? Apply that prediction to lung-cancers-01, option E: Reduced aldosterone-dependent distal sodium reabsorption.

      Mineralocorticoid deficiency can cause sodium loss with hypotension and hyperkalemia. For lung-cancers-01 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-01 option E, which supplied finding most strongly supports or refutes Reduced aldosterone-dependent distal sodium reabsorption?

      Normal adrenal function, clinical euvolemia, and the supplied urine pattern instead support ADH-mediated water retention. Thus, in lung-cancers-01 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Interpret plasma and urine together: dilute blood with persistently concentrated urine can reflect inappropriate ADH-mediated water retention.

Case sources: ^{[2] [5]}

1. A. Tumor production of PTH-related peptide (Best answer)

   Squamous carcinoma can produce PTHrP, which activates PTH receptors and promotes hypercalcemia with renal phosphate loss. High calcium suppresses endogenous intact PTH, so the low measured PTH does not contradict PTH-like biological effects.

   Reasoning steps for option A

   1. How can PTHrP have PTH-like effects when intact PTH is suppressed? Apply that prediction to lung-cancers-02, option A: Tumor production of PTH-related peptide.

      Squamous carcinoma can produce PTHrP, which activates PTH receptors and promotes hypercalcemia with renal phosphate loss. For lung-cancers-02 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-02 option A, which supplied finding most strongly supports or refutes Tumor production of PTH-related peptide?

      High calcium suppresses endogenous intact PTH, so the low measured PTH does not contradict PTH-like biological effects. Thus, in lung-cancers-02 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Autonomous secretion of intact PTH from a parathyroid adenoma (Why this does not fit)

   Primary hyperparathyroidism can produce high calcium and low phosphate. Its PTH would be high or inappropriately normal rather than suppressed to 5 pg/mL during substantial hypercalcemia.

   Reasoning steps for option B

   1. How should intact PTH behave in primary hyperparathyroidism? Apply that prediction to lung-cancers-02, option B: Autonomous secretion of intact PTH from a parathyroid adenoma.

      Primary hyperparathyroidism can produce high calcium and low phosphate. For lung-cancers-02 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-02 option B, which supplied finding most strongly supports or refutes Autonomous secretion of intact PTH from a parathyroid adenoma?

      Its PTH would be high or inappropriately normal rather than suppressed to 5 pg/mL during substantial hypercalcemia. Thus, in lung-cancers-02 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Excess renal activation of vitamin D driven by PTH (Why this does not fit)

   PTH stimulates renal calcitriol production, but measured PTH is suppressed here. The squamous phenotype and phosphate loss better support humoral PTHrP signaling than a PTH-driven process.

   Reasoning steps for option C

   1. What normally stimulates renal calcitriol production? Apply that prediction to lung-cancers-02, option C: Excess renal activation of vitamin D driven by PTH.

      PTH stimulates renal calcitriol production, but measured PTH is suppressed here. For lung-cancers-02 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-02 option C, which supplied finding most strongly supports or refutes Excess renal activation of vitamin D driven by PTH?

      The squamous phenotype and phosphate loss better support humoral PTHrP signaling than a PTH-driven process. Thus, in lung-cancers-02 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Ectopic antidiuretic hormone secretion (Why this does not fit)

   ADH primarily changes collecting-duct water permeability and can cause hypotonic hyponatremia. It does not explain this hypercalcemia, low phosphate, and suppressed intact PTH.

   Reasoning steps for option D

   1. Which variable does excess ADH primarily change? Apply that prediction to lung-cancers-02, option D: Ectopic antidiuretic hormone secretion.

      ADH primarily changes collecting-duct water permeability and can cause hypotonic hyponatremia. For lung-cancers-02 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-02 option D, which supplied finding most strongly supports or refutes Ectopic antidiuretic hormone secretion?

      It does not explain this hypercalcemia, low phosphate, and suppressed intact PTH. Thus, in lung-cancers-02 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Reduced calcium excretion caused by advanced renal failure (Why this does not fit)

   Advanced renal failure changes mineral handling and often raises phosphate and PTH. Normal renal function with low phosphate and suppressed PTH contradicts that explanation.

   Reasoning steps for option E

   1. What mineral pattern often accompanies advanced renal failure? Apply that prediction to lung-cancers-02, option E: Reduced calcium excretion caused by advanced renal failure.

      Advanced renal failure changes mineral handling and often raises phosphate and PTH. For lung-cancers-02 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-02 option E, which supplied finding most strongly supports or refutes Reduced calcium excretion caused by advanced renal failure?

      Normal renal function with low phosphate and suppressed PTH contradicts that explanation. Thus, in lung-cancers-02 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: PTHrP can produce PTH-like effects while intact PTH is appropriately suppressed; bone metastases are not required.

Case sources: ^{[1] [6]}

1. A. Loss of adrenal mineralocorticoid synthesis (Why this does not fit)

   Mineralocorticoid deficiency usually impairs potassium and acid excretion, causing hyperkalemia and metabolic acidosis. This patient's hypertension, low potassium, and alkalosis point in the opposite direction.

   Reasoning steps for option A

   1. How does deficient mineralocorticoid activity affect potassium and acid excretion? Apply that prediction to lung-cancers-03, option A: Loss of adrenal mineralocorticoid synthesis.

      Mineralocorticoid deficiency usually impairs potassium and acid excretion, causing hyperkalemia and metabolic acidosis. For lung-cancers-03 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-03 option A, which supplied finding most strongly supports or refutes Loss of adrenal mineralocorticoid synthesis?

      This patient's hypertension, low potassium, and alkalosis point in the opposite direction. Thus, in lung-cancers-03 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Excess insulin shifting potassium into cells as the sole disorder (Why this does not fit)

   Insulin can transiently lower serum potassium through cellular uptake. It does not explain the combined severe hypercortisolism, hypertension, and sustained metabolic alkalosis.

   Reasoning steps for option B

   1. What can insulin do to the measured potassium concentration? Apply that prediction to lung-cancers-03, option B: Excess insulin shifting potassium into cells as the sole disorder.

      Insulin can transiently lower serum potassium through cellular uptake. For lung-cancers-03 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-03 option B, which supplied finding most strongly supports or refutes Excess insulin shifting potassium into cells as the sole disorder?

      It does not explain the combined severe hypercortisolism, hypertension, and sustained metabolic alkalosis. Thus, in lung-cancers-03 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Failure of renal ammonium generation (Why this does not fit)

   Impaired ammonium excretion reduces renal acid elimination and tends to cause metabolic acidosis. The bicarbonate is high rather than low, so that mechanism does not fit.

   Reasoning steps for option C

   1. How does impaired ammonium excretion affect acid balance? Apply that prediction to lung-cancers-03, option C: Failure of renal ammonium generation.

      Impaired ammonium excretion reduces renal acid elimination and tends to cause metabolic acidosis. For lung-cancers-03 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-03 option C, which supplied finding most strongly supports or refutes Failure of renal ammonium generation?

      The bicarbonate is high rather than low, so that mechanism does not fit. Thus, in lung-cancers-03 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Primary adrenal cortisol production suppressing ACTH (Why this does not fit)

   An autonomous adrenal cortisol-producing tumor would usually suppress ACTH. The supplied high ACTH establishes an ACTH-dependent pattern, although additional work is needed to prove its source.

   Reasoning steps for option D

   1. What happens to ACTH in autonomous adrenal cortisol production? Apply that prediction to lung-cancers-03, option D: Primary adrenal cortisol production suppressing ACTH.

      An autonomous adrenal cortisol-producing tumor would usually suppress ACTH. For lung-cancers-03 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-03 option D, which supplied finding most strongly supports or refutes Primary adrenal cortisol production suppressing ACTH?

      The supplied high ACTH establishes an ACTH-dependent pattern, although additional work is needed to prove its source. Thus, in lung-cancers-03 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Severe cortisol excess producing renal mineralocorticoid effects (Best answer)

   Marked cortisol excess can overwhelm renal protection of mineralocorticoid receptors, promoting sodium retention and potassium and hydrogen ion loss. Rapid ectopic ACTH syndromes may present with this metabolic pattern before classic changes in body appearance develop.

   Reasoning steps for option E

   1. How can severe cortisol excess affect renal mineralocorticoid receptors? Apply that prediction to lung-cancers-03, option E: Severe cortisol excess producing renal mineralocorticoid effects.

      Marked cortisol excess can overwhelm renal protection of mineralocorticoid receptors, promoting sodium retention and potassium and hydrogen ion loss. For lung-cancers-03 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-03 option E, which supplied finding most strongly supports or refutes Severe cortisol excess producing renal mineralocorticoid effects?

      Rapid ectopic ACTH syndromes may present with this metabolic pattern before classic changes in body appearance develop. Thus, in lung-cancers-03 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Rapid ACTH-dependent hypercortisolism can present as hypertension, hypokalemia, and alkalosis without a classic long-standing appearance.

Case sources: ^{[2] [7]}

1. A. Urine sodium of 52 mmol/L with normal dietary salt intake (Why this does not fit)

   Urine sodium above 30 mmol/L can accompany inappropriate antidiuresis in a euvolemic patient. This value does not by itself refute the diagnosis, although volume status and other causes still matter.

   Reasoning steps for option A

   1. Can elevated urine sodium accompany inappropriate antidiuresis? Apply that prediction to lung-cancers-05, option A: Urine sodium of 52 mmol/L with normal dietary salt intake.

      Urine sodium above 30 mmol/L can accompany inappropriate antidiuresis in a euvolemic patient. For lung-cancers-05 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-05 option A, which supplied finding most strongly supports or refutes Urine sodium of 52 mmol/L with normal dietary salt intake?

      This value does not by itself refute the diagnosis, although volume status and other causes still matter. Thus, in lung-cancers-05 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Normal renal function without diuretic exposure (Why this does not fit)

   These findings help exclude alternative explanations and make the urine measurements easier to interpret. They support, rather than undermine, the proposed inappropriate-antidiuresis assessment.

   Reasoning steps for option B

   1. How do renal function and diuretic exposure affect interpretation? Apply that prediction to lung-cancers-05, option B: Normal renal function without diuretic exposure.

      These findings help exclude alternative explanations and make the urine measurements easier to interpret. For lung-cancers-05 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-05 option B, which supplied finding most strongly supports or refutes Normal renal function without diuretic exposure?

      They support, rather than undermine, the proposed inappropriate-antidiuresis assessment. Thus, in lung-cancers-05 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. No peripheral edema or ascites (Why this does not fit)

   Inappropriate antidiuresis is usually clinically euvolemic without overt peripheral edema. Absence of edema therefore does not require a competing endocrine diagnosis.

   Reasoning steps for option C

   1. Does inappropriate antidiuresis usually cause obvious edema? Apply that prediction to lung-cancers-05, option C: No peripheral edema or ascites.

      Inappropriate antidiuresis is usually clinically euvolemic without overt peripheral edema. For lung-cancers-05 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-05 option C, which supplied finding most strongly supports or refutes No peripheral edema or ascites?

      Absence of edema therefore does not require a competing endocrine diagnosis. Thus, in lung-cancers-05 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Low morning cortisol with hypotension and hyperkalemia (Best answer)

   Adrenal insufficiency can cause hypotonic hyponatremia with persistent antidiuresis, and primary adrenal failure can add hypotension and hyperkalemia. It must be evaluated rather than assuming that the known cancer explains every low sodium value.

   Reasoning steps for option D

   1. How can adrenal insufficiency cause hypotonic hyponatremia? Apply that prediction to lung-cancers-05, option D: Low morning cortisol with hypotension and hyperkalemia.

      Adrenal insufficiency can cause hypotonic hyponatremia with persistent antidiuresis, and primary adrenal failure can add hypotension and hyperkalemia. For lung-cancers-05 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-05 option D, which supplied finding most strongly supports or refutes Low morning cortisol with hypotension and hyperkalemia?

      It must be evaluated rather than assuming that the known cancer explains every low sodium value. Thus, in lung-cancers-05 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. A central tumor with neuroendocrine morphology (Why this does not fit)

   Small cell morphology increases the plausibility of ectopic ADH secretion. It is an association, not a replacement for exclusion criteria, but it does not itself point to a different endocrine cause.

   Reasoning steps for option E

   1. What does small cell histology contribute to the ADH hypothesis? Apply that prediction to lung-cancers-05, option E: A central tumor with neuroendocrine morphology.

      Small cell morphology increases the plausibility of ectopic ADH secretion. For lung-cancers-05 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-05 option E, which supplied finding most strongly supports or refutes A central tumor with neuroendocrine morphology?

      It is an association, not a replacement for exclusion criteria, but it does not itself point to a different endocrine cause. Thus, in lung-cancers-05 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: A familiar cancer association does not eliminate the need to exclude adrenal, thyroid, renal, medication, and volume-related causes of hyponatremia.

Case sources: ^{[2] [5]}

1. A. Squamous cell carcinoma (Why this does not fit)

   Smoking increases the risk of squamous carcinoma, but it is not exclusive to that histology. Gland formation, mucin, and the supplied immunophenotype support adenocarcinoma rather than squamous differentiation.

   Reasoning steps for option A

   1. Does smoking establish squamous differentiation? Apply that prediction to lung-cancers-06, option A: Squamous cell carcinoma.

      Smoking increases the risk of squamous carcinoma, but it is not exclusive to that histology. For lung-cancers-06 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-06 option A, which supplied finding most strongly supports or refutes Squamous cell carcinoma?

      Gland formation, mucin, and the supplied immunophenotype support adenocarcinoma rather than squamous differentiation. Thus, in lung-cancers-06 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Typical bronchial carcinoid (Why this does not fit)

   Carcinoid is a well-differentiated neuroendocrine tumor with organoid architecture and neuroendocrine features. The supplied glands, mucin, and adenocarcinoma-associated stains do not establish that phenotype.

   Reasoning steps for option B

   1. What differentiation pattern characterizes a carcinoid? Apply that prediction to lung-cancers-06, option B: Typical bronchial carcinoid.

      Carcinoid is a well-differentiated neuroendocrine tumor with organoid architecture and neuroendocrine features. For lung-cancers-06 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-06 option B, which supplied finding most strongly supports or refutes Typical bronchial carcinoid?

      The supplied glands, mucin, and adenocarcinoma-associated stains do not establish that phenotype. Thus, in lung-cancers-06 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Pulmonary adenocarcinoma (Best answer)

   Gland formation and mucin directly establish glandular differentiation, with TTF-1 and napsin A providing supporting evidence. Adenocarcinoma also occurs in smokers, so smoking does not override the tissue findings.

   Reasoning steps for option C

   1. What do glands and intracellular mucin demonstrate? Apply that prediction to lung-cancers-06, option C: Pulmonary adenocarcinoma.

      Gland formation and mucin directly establish glandular differentiation, with TTF-1 and napsin A providing supporting evidence. For lung-cancers-06 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-06 option C, which supplied finding most strongly supports or refutes Pulmonary adenocarcinoma?

      Adenocarcinoma also occurs in smokers, so smoking does not override the tissue findings. Thus, in lung-cancers-06 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Small cell carcinoma (Why this does not fit)

   Small cell carcinoma typically has scant cytoplasm, nuclear molding, and high-grade neuroendocrine morphology. The described gland-forming mucinous tumor has a different differentiation pattern.

   Reasoning steps for option D

   1. What cytology would favor small cell carcinoma? Apply that prediction to lung-cancers-06, option D: Small cell carcinoma.

      Small cell carcinoma typically has scant cytoplasm, nuclear molding, and high-grade neuroendocrine morphology. For lung-cancers-06 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-06 option D, which supplied finding most strongly supports or refutes Small cell carcinoma?

      The described gland-forming mucinous tumor has a different differentiation pattern. Thus, in lung-cancers-06 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Large cell carcinoma (Why this does not fit)

   Large cell carcinoma requires absence of identifiable glandular, squamous, or neuroendocrine differentiation on adequate assessment. Demonstrated glands and mucin exclude that undifferentiated category here.

   Reasoning steps for option E

   1. What must be absent before conventional large cell carcinoma is assigned? Apply that prediction to lung-cancers-06, option E: Large cell carcinoma.

      Large cell carcinoma requires absence of identifiable glandular, squamous, or neuroendocrine differentiation on adequate assessment. For lung-cancers-06 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-06 option E, which supplied finding most strongly supports or refutes Large cell carcinoma?

      Demonstrated glands and mucin exclude that undifferentiated category here. Thus, in lung-cancers-06 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Tissue differentiation outweighs a demographic stereotype: adenocarcinoma occurs in smokers as well as never-smokers.

Case sources: ^{[1] [3]}

1. A. Acinar adenocarcinoma because the lesion is peripheral (Why this does not fit)

   Peripheral location increases the probability of adenocarcinoma but is not diagnostic. Keratin pearls and intercellular bridges provide direct evidence of squamous differentiation rather than gland formation.

   Reasoning steps for option A

   1. How much diagnostic certainty does peripheral location provide? Apply that prediction to lung-cancers-07, option A: Acinar adenocarcinoma because the lesion is peripheral.

      Peripheral location increases the probability of adenocarcinoma but is not diagnostic. For lung-cancers-07 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-07 option A, which supplied finding most strongly supports or refutes Acinar adenocarcinoma because the lesion is peripheral?

      Keratin pearls and intercellular bridges provide direct evidence of squamous differentiation rather than gland formation. Thus, in lung-cancers-07 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Invasive mucinous adenocarcinoma because TTF-1 is negative (Why this does not fit)

   Some mucinous adenocarcinomas lack TTF-1, so a negative stain cannot establish squamous carcinoma alone. Here, however, definite keratinization, bridges, and p40 support squamous differentiation without a mucinous pattern.

   Reasoning steps for option B

   1. Can a mucinous adenocarcinoma lack TTF-1? Apply that prediction to lung-cancers-07, option B: Invasive mucinous adenocarcinoma because TTF-1 is negative.

      Some mucinous adenocarcinomas lack TTF-1, so a negative stain cannot establish squamous carcinoma alone. For lung-cancers-07 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-07 option B, which supplied finding most strongly supports or refutes Invasive mucinous adenocarcinoma because TTF-1 is negative?

      Here, however, definite keratinization, bridges, and p40 support squamous differentiation without a mucinous pattern. Thus, in lung-cancers-07 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Large cell carcinoma because smoking exposure is absent (Why this does not fit)

   Large cell carcinoma is defined by lack of specific differentiation, not by smoking status. The supplied keratin pearls and bridges establish a differentiated squamous phenotype.

   Reasoning steps for option C

   1. Is large cell carcinoma defined by smoking status? Apply that prediction to lung-cancers-07, option C: Large cell carcinoma because smoking exposure is absent.

      Large cell carcinoma is defined by lack of specific differentiation, not by smoking status. For lung-cancers-07 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-07 option C, which supplied finding most strongly supports or refutes Large cell carcinoma because smoking exposure is absent?

      The supplied keratin pearls and bridges establish a differentiated squamous phenotype. Thus, in lung-cancers-07 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Typical carcinoid because the patient has never smoked (Why this does not fit)

   Absent smoking exposure can occur with carcinoid, but it is not a neuroendocrine marker. Keratin pearls and intercellular bridges do not match a typical carcinoid's well-differentiated neuroendocrine architecture.

   Reasoning steps for option D

   1. Does never-smoking status establish neuroendocrine lineage? Apply that prediction to lung-cancers-07, option D: Typical carcinoid because the patient has never smoked.

      Absent smoking exposure can occur with carcinoid, but it is not a neuroendocrine marker. For lung-cancers-07 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-07 option D, which supplied finding most strongly supports or refutes Typical carcinoid because the patient has never smoked?

      Keratin pearls and intercellular bridges do not match a typical carcinoid's well-differentiated neuroendocrine architecture. Thus, in lung-cancers-07 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Squamous cell carcinoma despite the peripheral location (Best answer)

   Keratin pearls and intercellular bridges establish squamous differentiation, supported by strong p40. Atypical location or absent tobacco exposure must not overrule definite tissue findings.

   Reasoning steps for option E

   1. Which structures directly demonstrate squamous differentiation? Apply that prediction to lung-cancers-07, option E: Squamous cell carcinoma despite the peripheral location.

      Keratin pearls and intercellular bridges establish squamous differentiation, supported by strong p40. For lung-cancers-07 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-07 option E, which supplied finding most strongly supports or refutes Squamous cell carcinoma despite the peripheral location?

      Atypical location or absent tobacco exposure must not overrule definite tissue findings. Thus, in lung-cancers-07 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Location and exposure guide probabilities; definite morphology determines the histological classification.

Case sources: ^{[1] [3]}

1. A. Minimally invasive adenocarcinoma (Best answer)

   A small, lepidic-predominant tumor with an invasive component no greater than 5 mm can meet minimally invasive criteria when the relevant exclusion features are absent. The documented 3-mm focus prevents an in situ designation but remains within the minimal-invasion threshold.

   Reasoning steps for option A

   1. How do tumor size and measured invasion enter the minimally invasive category? Apply that prediction to lung-cancers-09, option A: Minimally invasive adenocarcinoma.

      A small, lepidic-predominant tumor with an invasive component no greater than 5 mm can meet minimally invasive criteria when the relevant exclusion features are absent. For lung-cancers-09 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-09 option A, which supplied finding most strongly supports or refutes Minimally invasive adenocarcinoma?

      The documented 3-mm focus prevents an in situ designation but remains within the minimal-invasion threshold. Thus, in lung-cancers-09 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Adenocarcinoma in situ (Why this does not fit)

   An in situ designation requires absence of invasion on adequate examination. The measured stromal invasive focus directly contradicts that requirement, even though most growth is lepidic.

   Reasoning steps for option B

   1. What invasion is permitted in adenocarcinoma in situ? Apply that prediction to lung-cancers-09, option B: Adenocarcinoma in situ.

      An in situ designation requires absence of invasion on adequate examination. For lung-cancers-09 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-09 option B, which supplied finding most strongly supports or refutes Adenocarcinoma in situ?

      The measured stromal invasive focus directly contradicts that requirement, even though most growth is lepidic. Thus, in lung-cancers-09 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Invasive mucinous adenocarcinoma established by lepidic growth alone (Why this does not fit)

   Lepidic describes a growth pattern rather than mucin production. No mucinous cell phenotype is supplied, so that specific subtype cannot be inferred from the architecture alone.

   Reasoning steps for option C

   1. Does lepidic architecture establish a mucinous phenotype? Apply that prediction to lung-cancers-09, option C: Invasive mucinous adenocarcinoma established by lepidic growth alone.

      Lepidic describes a growth pattern rather than mucin production. For lung-cancers-09 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-09 option C, which supplied finding most strongly supports or refutes Invasive mucinous adenocarcinoma established by lepidic growth alone?

      No mucinous cell phenotype is supplied, so that specific subtype cannot be inferred from the architecture alone. Thus, in lung-cancers-09 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Squamous cell carcinoma in situ (Why this does not fit)

   Squamous in situ disease involves a different epithelial differentiation pattern. This tumor is glandular and lepidic, and it also contains a documented stromal invasive focus.

   Reasoning steps for option D

   1. What tissue pattern belongs to squamous carcinoma in situ? Apply that prediction to lung-cancers-09, option D: Squamous cell carcinoma in situ.

      Squamous in situ disease involves a different epithelial differentiation pattern. For lung-cancers-09 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-09 option D, which supplied finding most strongly supports or refutes Squamous cell carcinoma in situ?

      This tumor is glandular and lepidic, and it also contains a documented stromal invasive focus. Thus, in lung-cancers-09 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Atypical adenomatous hyperplasia (Why this does not fit)

   Atypical adenomatous hyperplasia is a small preinvasive lesion, not a 2.4-cm adenocarcinoma with stromal invasion. The size and invasion rule out that precursor designation.

   Reasoning steps for option E

   1. What kind of lesion is atypical adenomatous hyperplasia? Apply that prediction to lung-cancers-09, option E: Atypical adenomatous hyperplasia.

      Atypical adenomatous hyperplasia is a small preinvasive lesion, not a 2.4-cm adenocarcinoma with stromal invasion. For lung-cancers-09 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-09 option E, which supplied finding most strongly supports or refutes Atypical adenomatous hyperplasia?

      The size and invasion rule out that precursor designation. Thus, in lung-cancers-09 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Lepidic growth is not synonymous with in situ disease; adequate sampling and measured invasion determine the category.

Case sources: ^[4]

1. A. Small cell carcinoma (Why this does not fit)

   Small cell carcinoma is a high-grade neuroendocrine carcinoma with brisk mitotic activity and often necrosis. The very low mitotic rate, uniform architecture, and absent necrosis oppose that diagnosis.

   Reasoning steps for option A

   1. What grade and mitotic pattern characterize small cell carcinoma? Apply that prediction to lung-cancers-10, option A: Small cell carcinoma.

      Small cell carcinoma is a high-grade neuroendocrine carcinoma with brisk mitotic activity and often necrosis. For lung-cancers-10 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-10 option A, which supplied finding most strongly supports or refutes Small cell carcinoma?

      The very low mitotic rate, uniform architecture, and absent necrosis oppose that diagnosis. Thus, in lung-cancers-10 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Large-cell neuroendocrine carcinoma (Why this does not fit)

   Large-cell neuroendocrine carcinoma is also high grade, with substantial mitotic activity and necrosis. Synaptophysin positivity does not override the low-grade morphology described here.

   Reasoning steps for option B

   1. Can positive synaptophysin alone establish a high-grade large-cell neuroendocrine tumor? Apply that prediction to lung-cancers-10, option B: Large-cell neuroendocrine carcinoma.

      Large-cell neuroendocrine carcinoma is also high grade, with substantial mitotic activity and necrosis. For lung-cancers-10 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-10 option B, which supplied finding most strongly supports or refutes Large-cell neuroendocrine carcinoma?

      Synaptophysin positivity does not override the low-grade morphology described here. Thus, in lung-cancers-10 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Atypical carcinoid (Why this does not fit)

   Atypical carcinoid has greater mitotic activity or necrosis than a typical carcinoid. The resection explicitly supplies low mitotic activity and no necrosis, supporting the typical category.

   Reasoning steps for option C

   1. What separates atypical from typical carcinoid? Apply that prediction to lung-cancers-10, option C: Atypical carcinoid.

      Atypical carcinoid has greater mitotic activity or necrosis than a typical carcinoid. For lung-cancers-10 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-10 option C, which supplied finding most strongly supports or refutes Atypical carcinoid?

      The resection explicitly supplies low mitotic activity and no necrosis, supporting the typical category. Thus, in lung-cancers-10 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Typical carcinoid (Best answer)

   A vascular obstructing endobronchial lesion with uniform neuroendocrine cells, fewer than 2 mitoses per 2 mm², and no necrosis fits typical carcinoid. Repeated infection in one lobe results from local obstruction rather than diffuse immunodeficiency.

   Reasoning steps for option D

   1. Which supplied resection findings fit typical carcinoid? Apply that prediction to lung-cancers-10, option D: Typical carcinoid.

      A vascular obstructing endobronchial lesion with uniform neuroendocrine cells, fewer than 2 mitoses per 2 mm², and no necrosis fits typical carcinoid. For lung-cancers-10 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-10 option D, which supplied finding most strongly supports or refutes Typical carcinoid?

      Repeated infection in one lobe results from local obstruction rather than diffuse immunodeficiency. Thus, in lung-cancers-10 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Poorly differentiated squamous cell carcinoma (Why this does not fit)

   Squamous carcinoma requires squamous differentiation or appropriate supporting evidence. The organoid neuroendocrine pattern, low mitotic activity, and synaptophysin expression instead support carcinoid.

   Reasoning steps for option E

   1. What evidence would be needed for squamous differentiation? Apply that prediction to lung-cancers-10, option E: Poorly differentiated squamous cell carcinoma.

      Squamous carcinoma requires squamous differentiation or appropriate supporting evidence. For lung-cancers-10 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-10 option E, which supplied finding most strongly supports or refutes Poorly differentiated squamous cell carcinoma?

      The organoid neuroendocrine pattern, low mitotic activity, and synaptophysin expression instead support carcinoid. Thus, in lung-cancers-10 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Neuroendocrine lineage and tumor grade are separate decisions; a shared marker does not make carcinoid small cell cancer.

Case sources: ^{[2] [3]}

1. A. Large-cell neuroendocrine carcinoma (Best answer)

   Large-cell cytology plus neuroendocrine architecture and supporting stains establishes a neuroendocrine phenotype. Extensive necrosis and brisk mitoses indicate a high-grade carcinoma rather than carcinoid.

   Reasoning steps for option A

   1. What establishes both neuroendocrine lineage and high grade here? Apply that prediction to lung-cancers-11, option A: Large-cell neuroendocrine carcinoma.

      Large-cell cytology plus neuroendocrine architecture and supporting stains establishes a neuroendocrine phenotype. For lung-cancers-11 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-11 option A, which supplied finding most strongly supports or refutes Large-cell neuroendocrine carcinoma?

      Extensive necrosis and brisk mitoses indicate a high-grade carcinoma rather than carcinoid. Thus, in lung-cancers-11 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Typical carcinoid (Why this does not fit)

   Typical carcinoid can express the same neuroendocrine markers. It does not fit the extensive necrosis, prominent nucleoli, and brisk mitotic activity of this high-grade tumor.

   Reasoning steps for option B

   1. Can a typical carcinoid share these neuroendocrine markers? Apply that prediction to lung-cancers-11, option B: Typical carcinoid.

      Typical carcinoid can express the same neuroendocrine markers. For lung-cancers-11 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-11 option B, which supplied finding most strongly supports or refutes Typical carcinoid?

      It does not fit the extensive necrosis, prominent nucleoli, and brisk mitotic activity of this high-grade tumor. Thus, in lung-cancers-11 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Large cell carcinoma without neuroendocrine differentiation (Why this does not fit)

   Conventional large cell carcinoma is an exclusion category without specific glandular, squamous, or neuroendocrine differentiation. Definite neuroendocrine architecture and stains contradict that absence here.

   Reasoning steps for option C

   1. What differentiation must conventional large cell carcinoma lack? Apply that prediction to lung-cancers-11, option C: Large cell carcinoma without neuroendocrine differentiation.

      Conventional large cell carcinoma is an exclusion category without specific glandular, squamous, or neuroendocrine differentiation. For lung-cancers-11 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-11 option C, which supplied finding most strongly supports or refutes Large cell carcinoma without neuroendocrine differentiation?

      Definite neuroendocrine architecture and stains contradict that absence here. Thus, in lung-cancers-11 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Adenocarcinoma in situ (Why this does not fit)

   In situ adenocarcinoma requires an appropriate lepidic glandular tumor without invasion. The large-cell neuroendocrine architecture, high-grade cytology, and extensive necrosis do not fit that category.

   Reasoning steps for option D

   1. What architecture and invasion status define in situ adenocarcinoma? Apply that prediction to lung-cancers-11, option D: Adenocarcinoma in situ.

      In situ adenocarcinoma requires an appropriate lepidic glandular tumor without invasion. For lung-cancers-11 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-11 option D, which supplied finding most strongly supports or refutes Adenocarcinoma in situ?

      The large-cell neuroendocrine architecture, high-grade cytology, and extensive necrosis do not fit that category. Thus, in lung-cancers-11 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Small cell carcinoma (Why this does not fit)

   Small cell carcinoma shares high-grade neuroendocrine behavior but typically has scant cytoplasm and inconspicuous nucleoli. The explicitly large cells, abundant cytoplasm, and prominent nucleoli favor large-cell neuroendocrine carcinoma.

   Reasoning steps for option E

   1. What cytology usually distinguishes small cell carcinoma? Apply that prediction to lung-cancers-11, option E: Small cell carcinoma.

      Small cell carcinoma shares high-grade neuroendocrine behavior but typically has scant cytoplasm and inconspicuous nucleoli. For lung-cancers-11 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-11 option E, which supplied finding most strongly supports or refutes Small cell carcinoma?

      The explicitly large cells, abundant cytoplasm, and prominent nucleoli favor large-cell neuroendocrine carcinoma. Thus, in lung-cancers-11 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Large-cell neuroendocrine carcinoma is not the same diagnosis as marker-negative large cell carcinoma.

Case sources: ^{[2] [3]}

1. A. Upper brachial plexus and phrenic nerve (Why this does not fit)

   Upper plexus injury mainly affects C5-C6 functions such as shoulder abduction, while phrenic injury affects the diaphragm. Neither explains the supplied lower-plexus hand distribution plus Horner findings.

   Reasoning steps for option A

   1. Which functions are associated with the upper plexus and phrenic nerve? Apply that prediction to lung-cancers-12, option A: Upper brachial plexus and phrenic nerve.

      Upper plexus injury mainly affects C5-C6 functions such as shoulder abduction, while phrenic injury affects the diaphragm. For lung-cancers-12 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-12 option A, which supplied finding most strongly supports or refutes Upper brachial plexus and phrenic nerve?

      Neither explains the supplied lower-plexus hand distribution plus Horner findings. Thus, in lung-cancers-12 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Left recurrent laryngeal nerve and thoracic duct (Why this does not fit)

   Recurrent laryngeal injury produces vocal fold dysfunction, and thoracic duct injury can cause a chylous effusion. Those effects do not account for intrinsic hand weakness and sympathetic ocular findings.

   Reasoning steps for option B

   1. What would recurrent laryngeal and thoracic duct injury produce? Apply that prediction to lung-cancers-12, option B: Left recurrent laryngeal nerve and thoracic duct.

      Recurrent laryngeal injury produces vocal fold dysfunction, and thoracic duct injury can cause a chylous effusion. For lung-cancers-12 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-12 option B, which supplied finding most strongly supports or refutes Left recurrent laryngeal nerve and thoracic duct?

      Those effects do not account for intrinsic hand weakness and sympathetic ocular findings. Thus, in lung-cancers-12 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Long thoracic nerve and cervical parasympathetic fibers (Why this does not fit)

   Long thoracic injury causes serratus anterior weakness and scapular winging. Horner syndrome reflects sympathetic interruption, not loss of parasympathetic input.

   Reasoning steps for option C

   1. What deficit follows long thoracic nerve injury? Apply that prediction to lung-cancers-12, option C: Long thoracic nerve and cervical parasympathetic fibers.

      Long thoracic injury causes serratus anterior weakness and scapular winging. For lung-cancers-12 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-12 option C, which supplied finding most strongly supports or refutes Long thoracic nerve and cervical parasympathetic fibers?

      Horner syndrome reflects sympathetic interruption, not loss of parasympathetic input. Thus, in lung-cancers-12 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Lower brachial plexus and preganglionic sympathetic pathway (Best answer)

   C8-T1 lower-plexus involvement accounts for ulnar-sided symptoms and intrinsic hand weakness. An apical lesion can also interrupt the nearby ascending preganglionic sympathetic pathway, producing ipsilateral Horner syndrome.

   Reasoning steps for option D

   1. Which hand functions depend on the lower brachial plexus? Apply that prediction to lung-cancers-12, option D: Lower brachial plexus and preganglionic sympathetic pathway.

      C8-T1 lower-plexus involvement accounts for ulnar-sided symptoms and intrinsic hand weakness. For lung-cancers-12 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-12 option D, which supplied finding most strongly supports or refutes Lower brachial plexus and preganglionic sympathetic pathway?

      An apical lesion can also interrupt the nearby ascending preganglionic sympathetic pathway, producing ipsilateral Horner syndrome. Thus, in lung-cancers-12 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Superior vena cava and vagus nerve (Why this does not fit)

   SVC obstruction causes upper-body venous congestion, and vagal involvement can affect laryngeal or autonomic function. That pairing does not localize the focal hand deficit and classic sympathetic ocular pattern.

   Reasoning steps for option E

   1. What patterns would SVC obstruction and vagal involvement cause? Apply that prediction to lung-cancers-12, option E: Superior vena cava and vagus nerve.

      SVC obstruction causes upper-body venous congestion, and vagal involvement can affect laryngeal or autonomic function. For lung-cancers-12 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-12 option E, which supplied finding most strongly supports or refutes Superior vena cava and vagus nerve?

      That pairing does not localize the focal hand deficit and classic sympathetic ocular pattern. Thus, in lung-cancers-12 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Pancoast syndrome is a thoracic inlet localization, not a histological diagnosis.

Case sources: ^[1]

1. A. Left brachiocephalic vein (Why this does not fit)

   Left brachiocephalic obstruction primarily impairs drainage from the left upper limb and left side of the head and neck. The isolated right-arm distribution and right apical lesion point elsewhere.

   Reasoning steps for option A

   1. Which upper limb drains through the left brachiocephalic vein? Apply that prediction to lung-cancers-13, option A: Left brachiocephalic vein.

      Left brachiocephalic obstruction primarily impairs drainage from the left upper limb and left side of the head and neck. For lung-cancers-13 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-13 option A, which supplied finding most strongly supports or refutes Left brachiocephalic vein?

      The isolated right-arm distribution and right apical lesion point elsewhere. Thus, in lung-cancers-13 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Right subclavian vein (Best answer)

   The right subclavian vein carries blood from the right upper limb and lies near the lung apex. Its compression can cause ipsilateral arm swelling without the broader facial and bilateral upper-limb congestion of SVC obstruction.

   Reasoning steps for option B

   1. What venous territory does the right subclavian vein drain? Apply that prediction to lung-cancers-13, option B: Right subclavian vein.

      The right subclavian vein carries blood from the right upper limb and lies near the lung apex. For lung-cancers-13 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-13 option B, which supplied finding most strongly supports or refutes Right subclavian vein?

      Its compression can cause ipsilateral arm swelling without the broader facial and bilateral upper-limb congestion of SVC obstruction. Thus, in lung-cancers-13 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Inferior vena cava (Why this does not fit)

   Inferior vena cava obstruction predominantly impairs venous drainage from the lower body. It does not explain isolated right-arm edema at the thoracic inlet.

   Reasoning steps for option C

   1. Which body region drains through the inferior vena cava? Apply that prediction to lung-cancers-13, option C: Inferior vena cava.

      Inferior vena cava obstruction predominantly impairs venous drainage from the lower body. For lung-cancers-13 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-13 option C, which supplied finding most strongly supports or refutes Inferior vena cava?

      It does not explain isolated right-arm edema at the thoracic inlet. Thus, in lung-cancers-13 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Left pulmonary vein (Why this does not fit)

   Pulmonary veins drain the lungs into the left atrium rather than draining the arm. Left pulmonary venous obstruction would not directly produce isolated right upper-limb swelling.

   Reasoning steps for option D

   1. What do pulmonary veins drain? Apply that prediction to lung-cancers-13, option D: Left pulmonary vein.

      Pulmonary veins drain the lungs into the left atrium rather than draining the arm. For lung-cancers-13 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-13 option D, which supplied finding most strongly supports or refutes Left pulmonary vein?

      Left pulmonary venous obstruction would not directly produce isolated right upper-limb swelling. Thus, in lung-cancers-13 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Azygos vein below its arch (Why this does not fit)

   The azygos system provides thoracic venous drainage and collateral pathways. The focal right-arm distribution next to an apical lesion is more directly explained by subclavian obstruction.

   Reasoning steps for option E

   1. What is the role of the azygos venous system? Apply that prediction to lung-cancers-13, option E: Azygos vein below its arch.

      The azygos system provides thoracic venous drainage and collateral pathways. For lung-cancers-13 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-13 option E, which supplied finding most strongly supports or refutes Azygos vein below its arch?

      The focal right-arm distribution next to an apical lesion is more directly explained by subclavian obstruction. Thus, in lung-cancers-13 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: The distribution of edema identifies the obstructed venous territory; unilateral arm edema is not automatically SVC syndrome.

Case sources: ^[1]

1. A. Right recurrent laryngeal nerve at the subclavian artery (Why this does not fit)

   The right recurrent laryngeal nerve loops under the right subclavian artery. That location and side do not match left vocal fold paralysis with an aortopulmonary-window lesion.

   Reasoning steps for option A

   1. Where does the right recurrent laryngeal nerve loop? Apply that prediction to lung-cancers-14, option A: Right recurrent laryngeal nerve at the subclavian artery.

      The right recurrent laryngeal nerve loops under the right subclavian artery. For lung-cancers-14 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-14 option A, which supplied finding most strongly supports or refutes Right recurrent laryngeal nerve at the subclavian artery?

      That location and side do not match left vocal fold paralysis with an aortopulmonary-window lesion. Thus, in lung-cancers-14 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Left phrenic nerve (Why this does not fit)

   Phrenic injury impairs the ipsilateral hemidiaphragm. Normal diaphragmatic function and documented vocal fold paralysis instead localize to laryngeal innervation.

   Reasoning steps for option B

   1. What muscle does the phrenic nerve supply? Apply that prediction to lung-cancers-14, option B: Left phrenic nerve.

      Phrenic injury impairs the ipsilateral hemidiaphragm. For lung-cancers-14 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-14 option B, which supplied finding most strongly supports or refutes Left phrenic nerve?

      Normal diaphragmatic function and documented vocal fold paralysis instead localize to laryngeal innervation. Thus, in lung-cancers-14 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Lower trunk of the left brachial plexus (Why this does not fit)

   Lower plexus involvement affects medial arm or hand sensation and intrinsic hand function. It does not directly explain an isolated paralyzed vocal fold.

   Reasoning steps for option C

   1. What deficits would lower brachial plexus injury produce? Apply that prediction to lung-cancers-14, option C: Lower trunk of the left brachial plexus.

      Lower plexus involvement affects medial arm or hand sensation and intrinsic hand function. For lung-cancers-14 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-14 option C, which supplied finding most strongly supports or refutes Lower trunk of the left brachial plexus?

      It does not directly explain an isolated paralyzed vocal fold. Thus, in lung-cancers-14 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Left cervical sympathetic pathway (Why this does not fit)

   Sympathetic interruption causes Horner findings such as miosis and ptosis. It does not provide the motor innervation responsible for the observed vocal fold paralysis.

   Reasoning steps for option D

   1. What ocular findings follow sympathetic interruption? Apply that prediction to lung-cancers-14, option D: Left cervical sympathetic pathway.

      Sympathetic interruption causes Horner findings such as miosis and ptosis. For lung-cancers-14 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-14 option D, which supplied finding most strongly supports or refutes Left cervical sympathetic pathway?

      It does not provide the motor innervation responsible for the observed vocal fold paralysis. Thus, in lung-cancers-14 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Left recurrent laryngeal nerve beneath the aortic arch (Best answer)

   The left recurrent laryngeal nerve passes beneath the aortic arch before ascending toward the larynx. Aortopulmonary-window disease can therefore produce left vocal fold paresis and hoarseness while sparing diaphragmatic function.

   Reasoning steps for option E

   1. Where does the left recurrent laryngeal nerve pass in the thorax? Apply that prediction to lung-cancers-14, option E: Left recurrent laryngeal nerve beneath the aortic arch.

      The left recurrent laryngeal nerve passes beneath the aortic arch before ascending toward the larynx. For lung-cancers-14 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-14 option E, which supplied finding most strongly supports or refutes Left recurrent laryngeal nerve beneath the aortic arch?

      Aortopulmonary-window disease can therefore produce left vocal fold paresis and hoarseness while sparing diaphragmatic function. Thus, in lung-cancers-14 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Combine side, nerve function, and anatomical course rather than assigning every thoracic nerve symptom to an apical tumor.

Case sources: ^[1]

1. A. Start a squamous-specific chemotherapy regimen based on the swelling pattern (Why this does not fit)

   SVC obstruction can be caused by several malignancies, including different lung cancers and lymphoma. The venous pattern does not establish the histology needed to choose a tumor-specific regimen.

   Reasoning steps for option A

   1. Does SVC obstruction identify one specific tumor histology? Apply that prediction to lung-cancers-15, option A: Start a squamous-specific chemotherapy regimen based on the swelling pattern.

      SVC obstruction can be caused by several malignancies, including different lung cancers and lymphoma. For lung-cancers-15 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-15 option A, which supplied finding most strongly supports or refutes Start a squamous-specific chemotherapy regimen based on the swelling pattern?

      The venous pattern does not establish the histology needed to choose a tumor-specific regimen. Thus, in lung-cancers-15 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Assign small cell histology from the central location alone (Why this does not fit)

   Central location and SVC compression can occur with small cell cancer but are not diagnostic. Tissue confirmation is available and materially changes the appropriate therapy.

   Reasoning steps for option B

   1. Can central location establish small cell histology without tissue? Apply that prediction to lung-cancers-15, option B: Assign small cell histology from the central location alone.

      Central location and SVC compression can occur with small cell cancer but are not diagnostic. For lung-cancers-15 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-15 option B, which supplied finding most strongly supports or refutes Assign small cell histology from the central location alone?

      Tissue confirmation is available and materially changes the appropriate therapy. Thus, in lung-cancers-15 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Obtain tissue diagnosis promptly while monitoring for clinical deterioration (Best answer)

   This patient has confirmed obstruction but no supplied airway, cerebral, or circulatory emergency. Prompt tissue diagnosis permits appropriate tumor-directed treatment, while close monitoring and symptom management address the risk of worsening obstruction.

   Reasoning steps for option C

   1. Which supplied findings make prompt biopsy a reasonable priority? Apply that prediction to lung-cancers-15, option C: Obtain tissue diagnosis promptly while monitoring for clinical deterioration.

      This patient has confirmed obstruction but no supplied airway, cerebral, or circulatory emergency. For lung-cancers-15 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-15 option C, which supplied finding most strongly supports or refutes Obtain tissue diagnosis promptly while monitoring for clinical deterioration?

      Prompt tissue diagnosis permits appropriate tumor-directed treatment, while close monitoring and symptom management address the risk of worsening obstruction. Thus, in lung-cancers-15 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Use a normal oxygen saturation to exclude clinically important venous obstruction (Why this does not fit)

   Oxygen saturation measures arterial oxygenation, not central venous drainage. CT and the upper-body congestion establish SVC obstruction despite a normal saturation.

   Reasoning steps for option D

   1. What does a normal oxygen saturation actually measure? Apply that prediction to lung-cancers-15, option D: Use a normal oxygen saturation to exclude clinically important venous obstruction.

      Oxygen saturation measures arterial oxygenation, not central venous drainage. For lung-cancers-15 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-15 option D, which supplied finding most strongly supports or refutes Use a normal oxygen saturation to exclude clinically important venous obstruction?

      CT and the upper-body congestion establish SVC obstruction despite a normal saturation. Thus, in lung-cancers-15 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Give definitive thoracic radiation before any attempt at diagnosis solely because SVC narrowing is present (Why this does not fit)

   Radiation can relieve malignant obstruction, but its appropriateness depends on histology and the clinical situation. In this stable, promptly biopsy-accessible patient, radiographic narrowing alone does not justify bypassing diagnosis.

   Reasoning steps for option E

   1. Why can the choice of definitive radiation depend on tissue diagnosis? Apply that prediction to lung-cancers-15, option E: Give definitive thoracic radiation before any attempt at diagnosis solely because SVC narrowing is present.

      Radiation can relieve malignant obstruction, but its appropriateness depends on histology and the clinical situation. For lung-cancers-15 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-15 option E, which supplied finding most strongly supports or refutes Give definitive thoracic radiation before any attempt at diagnosis solely because SVC narrowing is present?

      In this stable, promptly biopsy-accessible patient, radiographic narrowing alone does not justify bypassing diagnosis. Thus, in lung-cancers-15 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Distinguish urgent stabilization from definitive cancer treatment: stable SVC obstruction still requires histological diagnosis.

Case sources: ^{[1] [2] [20]}

1. A. Urgent airway stabilization and specialist assessment for endovascular decompression (Best answer)

   Stridor and neurological deterioration indicate a potentially life-threatening obstruction rather than uncomplicated venous congestion. Stabilizing the airway and considering rapid endovascular decompression address the immediate physiology while definitive oncological care is arranged.

   Reasoning steps for option A

   1. Which symptoms make this obstruction immediately dangerous? Apply that prediction to lung-cancers-16, option A: Urgent airway stabilization and specialist assessment for endovascular decompression.

      Stridor and neurological deterioration indicate a potentially life-threatening obstruction rather than uncomplicated venous congestion. For lung-cancers-16 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-16 option A, which supplied finding most strongly supports or refutes Urgent airway stabilization and specialist assessment for endovascular decompression?

      Stabilizing the airway and considering rapid endovascular decompression address the immediate physiology while definitive oncological care is arranged. Thus, in lung-cancers-16 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Outpatient biopsy followed by observation until histology returns (Why this does not fit)

   Obtaining histology is essential for definitive cancer therapy in a stable patient. It cannot replace emergency stabilization when laryngeal edema and neurological deterioration are already present.

   Reasoning steps for option B

   1. When is tissue-first sequencing appropriate? Apply that prediction to lung-cancers-16, option B: Outpatient biopsy followed by observation until histology returns.

      Obtaining histology is essential for definitive cancer therapy in a stable patient. For lung-cancers-16 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-16 option B, which supplied finding most strongly supports or refutes Outpatient biopsy followed by observation until histology returns?

      It cannot replace emergency stabilization when laryngeal edema and neurological deterioration are already present. Thus, in lung-cancers-16 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Anticoagulation alone as treatment of the external compression (Why this does not fit)

   Anticoagulation addresses thrombotic disease but does not directly relieve severe external tumor compression. No intraluminal thrombus is supplied, and the airway and cerebral warning signs require more immediate intervention.

   Reasoning steps for option C

   1. What component of venous obstruction does anticoagulation address? Apply that prediction to lung-cancers-16, option C: Anticoagulation alone as treatment of the external compression.

      Anticoagulation addresses thrombotic disease but does not directly relieve severe external tumor compression. For lung-cancers-16 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-16 option C, which supplied finding most strongly supports or refutes Anticoagulation alone as treatment of the external compression?

      No intraluminal thrombus is supplied, and the airway and cerebral warning signs require more immediate intervention. Thus, in lung-cancers-16 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Wait for several weeks of systemic therapy before reassessing airway symptoms (Why this does not fit)

   Tumor-directed systemic therapy may improve malignant obstruction, depending on histology. Waiting for tumor shrinkage without stabilizing an already threatened airway is not appropriate for the described presentation.

   Reasoning steps for option D

   1. How can systemic cancer therapy affect malignant obstruction? Apply that prediction to lung-cancers-16, option D: Wait for several weeks of systemic therapy before reassessing airway symptoms.

      Tumor-directed systemic therapy may improve malignant obstruction, depending on histology. For lung-cancers-16 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-16 option D, which supplied finding most strongly supports or refutes Wait for several weeks of systemic therapy before reassessing airway symptoms?

      Waiting for tumor shrinkage without stabilizing an already threatened airway is not appropriate for the described presentation. Thus, in lung-cancers-16 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Use diuresis alone to correct the venous obstruction (Why this does not fit)

   Diuresis may alter fluid balance but does not reopen a mechanically obstructed SVC. It is not an adequate sole response to rapidly worsening airway edema and confusion.

   Reasoning steps for option E

   1. Does changing total fluid volume reopen a compressed SVC? Apply that prediction to lung-cancers-16, option E: Use diuresis alone to correct the venous obstruction.

      Diuresis may alter fluid balance but does not reopen a mechanically obstructed SVC. For lung-cancers-16 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-16 option E, which supplied finding most strongly supports or refutes Use diuresis alone to correct the venous obstruction?

      It is not an adequate sole response to rapidly worsening airway edema and confusion. Thus, in lung-cancers-16 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Severe SVC-related airway or cerebral compromise changes the priority from diagnostic sequencing to immediate stabilization and rapid decompression assessment.

Case sources: ^{[1] [20]}

1. A. Absence of liver metastases proves the urinary results are false positives (Why this does not fit)

   Collection problems can affect 5-HIAA results, but appropriate repeated testing and a compatible syndrome make automatic dismissal unjustified. Bronchial tumors can produce systemic hormone effects without hepatic metastases.

   Reasoning steps for option A

   1. Can a functioning bronchial primary cause hormone effects without liver metastases? Apply that prediction to lung-cancers-17, option A: Absence of liver metastases proves the urinary results are false positives.

      Collection problems can affect 5-HIAA results, but appropriate repeated testing and a compatible syndrome make automatic dismissal unjustified. For lung-cancers-17 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-17 option A, which supplied finding most strongly supports or refutes Absence of liver metastases proves the urinary results are false positives?

      Bronchial tumors can produce systemic hormone effects without hepatic metastases. Thus, in lung-cancers-17 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Every bronchial carcinoid releases enough serotonin to produce the syndrome (Why this does not fit)

   Many bronchial carcinoids do not cause carcinoid syndrome. The relevant explanation is the combination of a functioning tumor and its drainage, not a universal secretory property of all carcinoids.

   Reasoning steps for option B

   1. Do all bronchial carcinoids cause the endocrine syndrome? Apply that prediction to lung-cancers-17, option B: Every bronchial carcinoid releases enough serotonin to produce the syndrome.

      Many bronchial carcinoids do not cause carcinoid syndrome. For lung-cancers-17 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-17 option B, which supplied finding most strongly supports or refutes Every bronchial carcinoid releases enough serotonin to produce the syndrome?

      The relevant explanation is the combination of a functioning tumor and its drainage, not a universal secretory property of all carcinoids. Thus, in lung-cancers-17 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Serotonin can act only after conversion by metastatic liver tissue (Why this does not fit)

   Hepatic metabolism usually inactivates circulating mediators rather than being required to activate their systemic effects. A tumor outside portal drainage can bypass that initial clearance.

   Reasoning steps for option C

   1. Does hepatic metabolism activate serotonin or usually clear mediators? Apply that prediction to lung-cancers-17, option C: Serotonin can act only after conversion by metastatic liver tissue.

      Hepatic metabolism usually inactivates circulating mediators rather than being required to activate their systemic effects. For lung-cancers-17 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-17 option C, which supplied finding most strongly supports or refutes Serotonin can act only after conversion by metastatic liver tissue?

      A tumor outside portal drainage can bypass that initial clearance. Thus, in lung-cancers-17 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. The bronchial primary can release mediators into systemic drainage outside portal first-pass clearance (Best answer)

   A functioning bronchial tumor can deliver mediators to the systemic circulation without first passing through portal hepatic clearance. Liver metastases are common in carcinoid syndrome overall, but they are not obligatory for this primary site.

   Reasoning steps for option D

   1. How can bronchial tumor drainage bypass portal first-pass clearance? Apply that prediction to lung-cancers-17, option D: The bronchial primary can release mediators into systemic drainage outside portal first-pass clearance.

      A functioning bronchial tumor can deliver mediators to the systemic circulation without first passing through portal hepatic clearance. For lung-cancers-17 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-17 option D, which supplied finding most strongly supports or refutes The bronchial primary can release mediators into systemic drainage outside portal first-pass clearance?

      Liver metastases are common in carcinoid syndrome overall, but they are not obligatory for this primary site. Thus, in lung-cancers-17 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Small cell histology is required whenever a pulmonary tumor causes diarrhea (Why this does not fit)

   Small cell carcinoma is associated with several endocrine syndromes, but diarrhea does not establish its histology. The identified functioning bronchial neuroendocrine tumor and serotonin metabolite pattern explain this presentation.

   Reasoning steps for option E

   1. Does diarrhea determine the histology of a lung tumor? Apply that prediction to lung-cancers-17, option E: Small cell histology is required whenever a pulmonary tumor causes diarrhea.

      Small cell carcinoma is associated with several endocrine syndromes, but diarrhea does not establish its histology. For lung-cancers-17 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-17 option E, which supplied finding most strongly supports or refutes Small cell histology is required whenever a pulmonary tumor causes diarrhea?

      The identified functioning bronchial neuroendocrine tumor and serotonin metabolite pattern explain this presentation. Thus, in lung-cancers-17 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Carcinoid hormone effects depend on tumor function and venous drainage, not a universal requirement for liver metastases.

Case sources: ^[10]

1. A. Serum tryptase (Why this does not fit)

   Mast-cell activation can cause flushing and gastrointestinal symptoms. Tryptase assesses that alternative process rather than providing biochemical evidence of sustained serotonin excess.

   Reasoning steps for option A

   1. Which competing process can serum tryptase assess? Apply that prediction to lung-cancers-18, option A: Serum tryptase.

      Mast-cell activation can cause flushing and gastrointestinal symptoms. For lung-cancers-18 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-18 option A, which supplied finding most strongly supports or refutes Serum tryptase?

      Tryptase assesses that alternative process rather than providing biochemical evidence of sustained serotonin excess. Thus, in lung-cancers-18 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Urinary 5-hydroxyindoleacetic acid in a properly collected sample (Best answer)

   5-HIAA is a major serotonin metabolite and supports the suspected functional syndrome. Collection quality, diet, and interfering medications matter when interpreting the result.

   Reasoning steps for option B

   1. What is 5-HIAA a metabolite of? Apply that prediction to lung-cancers-18, option B: Urinary 5-hydroxyindoleacetic acid in a properly collected sample.

      5-HIAA is a major serotonin metabolite and supports the suspected functional syndrome. For lung-cancers-18 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-18 option B, which supplied finding most strongly supports or refutes Urinary 5-hydroxyindoleacetic acid in a properly collected sample?

      Collection quality, diet, and interfering medications matter when interpreting the result. Thus, in lung-cancers-18 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Serum chromogranin A (Why this does not fit)

   Chromogranin A can be associated with neuroendocrine tumors but is nonspecific and affected by several non-tumor factors. It does not directly assess serotonin metabolism as the requested 5-HIAA measurement does.

   Reasoning steps for option C

   1. How specific is chromogranin A for serotonin secretion? Apply that prediction to lung-cancers-18, option C: Serum chromogranin A.

      Chromogranin A can be associated with neuroendocrine tumors but is nonspecific and affected by several non-tumor factors. For lung-cancers-18 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-18 option C, which supplied finding most strongly supports or refutes Serum chromogranin A?

      It does not directly assess serotonin metabolism as the requested 5-HIAA measurement does. Thus, in lung-cancers-18 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Fasting serum gastrin (Why this does not fit)

   Gastrin evaluates gastrinoma-related acid hypersecretion, which may also cause diarrhea. It does not measure serotonin excess or best explain the recurrent flushing with a functioning bronchial tumor.

   Reasoning steps for option D

   1. What secretory disorder is investigated with fasting gastrin? Apply that prediction to lung-cancers-18, option D: Fasting serum gastrin.

      Gastrin evaluates gastrinoma-related acid hypersecretion, which may also cause diarrhea. For lung-cancers-18 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-18 option D, which supplied finding most strongly supports or refutes Fasting serum gastrin?

      It does not measure serotonin excess or best explain the recurrent flushing with a functioning bronchial tumor. Thus, in lung-cancers-18 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Plasma free metanephrines (Why this does not fit)

   Metanephrines evaluate catecholamine secretion and can help assess an alternative episodic autonomic syndrome. They are not a measurement of serotonin production in this clinical setting.

   Reasoning steps for option E

   1. What hormone system is assessed using plasma metanephrines? Apply that prediction to lung-cancers-18, option E: Plasma free metanephrines.

      Metanephrines evaluate catecholamine secretion and can help assess an alternative episodic autonomic syndrome. For lung-cancers-18 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-18 option E, which supplied finding most strongly supports or refutes Plasma free metanephrines?

      They are not a measurement of serotonin production in this clinical setting. Thus, in lung-cancers-18 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Use 5-HIAA to investigate serotonin excess, with proper preparation; tissue markers and unrelated paraneoplastic tests answer different questions.

Case sources: ^[10]

1. A. Multiple destructive bone metastases established by any cancer-associated bone pain (Why this does not fit)

   Cancer-related bone pain requires evaluation, but pain alone does not establish metastases. The supplied symmetric periosteal reaction and clubbing are a different pattern from focal destructive deposits.

   Reasoning steps for option A

   1. Does cancer-associated bone pain alone establish skeletal metastases? Apply that prediction to lung-cancers-19, option A: Multiple destructive bone metastases established by any cancer-associated bone pain.

      Cancer-related bone pain requires evaluation, but pain alone does not establish metastases. For lung-cancers-19 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-19 option A, which supplied finding most strongly supports or refutes Multiple destructive bone metastases established by any cancer-associated bone pain?

      The supplied symmetric periosteal reaction and clubbing are a different pattern from focal destructive deposits. Thus, in lung-cancers-19 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Primary hyperparathyroidism established by clubbing (Why this does not fit)

   Primary hyperparathyroidism has characteristic biochemical and skeletal manifestations, but clubbing does not establish it. No inappropriate PTH or hypercalcemia is supplied, and the periosteal pattern fits another process.

   Reasoning steps for option B

   1. Does clubbing establish a PTH-dependent calcium disorder? Apply that prediction to lung-cancers-19, option B: Primary hyperparathyroidism established by clubbing.

      Primary hyperparathyroidism has characteristic biochemical and skeletal manifestations, but clubbing does not establish it. For lung-cancers-19 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-19 option B, which supplied finding most strongly supports or refutes Primary hyperparathyroidism established by clubbing?

      No inappropriate PTH or hypercalcemia is supplied, and the periosteal pattern fits another process. Thus, in lung-cancers-19 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Hypertrophic osteoarthropathy associated with the pulmonary tumor (Best answer)

   Clubbing, arthralgia, and symmetric periosteal new bone formation form the hypertrophic osteoarthropathy pattern. This paraneoplastic association can accompany NSCLC and does not itself prove skeletal metastasis or a unique histology.

   Reasoning steps for option C

   1. Which findings form the hypertrophic osteoarthropathy pattern? Apply that prediction to lung-cancers-19, option C: Hypertrophic osteoarthropathy associated with the pulmonary tumor.

      Clubbing, arthralgia, and symmetric periosteal new bone formation form the hypertrophic osteoarthropathy pattern. For lung-cancers-19 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-19 option C, which supplied finding most strongly supports or refutes Hypertrophic osteoarthropathy associated with the pulmonary tumor?

      This paraneoplastic association can accompany NSCLC and does not itself prove skeletal metastasis or a unique histology. Thus, in lung-cancers-19 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Direct extension of the apical tumor into all four distal limbs (Why this does not fit)

   Local extension can affect nearby chest wall or neural structures. It cannot anatomically explain symmetric periosteal changes in distant upper and lower limbs.

   Reasoning steps for option D

   1. What anatomical reach can direct extension of an apical tumor have? Apply that prediction to lung-cancers-19, option D: Direct extension of the apical tumor into all four distal limbs.

      Local extension can affect nearby chest wall or neural structures. For lung-cancers-19 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-19 option D, which supplied finding most strongly supports or refutes Direct extension of the apical tumor into all four distal limbs?

      It cannot anatomically explain symmetric periosteal changes in distant upper and lower limbs. Thus, in lung-cancers-19 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Lambert-Eaton syndrome producing periosteal new bone (Why this does not fit)

   Lambert-Eaton syndrome impairs presynaptic neuromuscular transmission and produces weakness with autonomic features. It does not explain clubbing and radiographic periosteal bone formation.

   Reasoning steps for option E

   1. What physiological process is impaired in Lambert-Eaton syndrome? Apply that prediction to lung-cancers-19, option E: Lambert-Eaton syndrome producing periosteal new bone.

      Lambert-Eaton syndrome impairs presynaptic neuromuscular transmission and produces weakness with autonomic features. For lung-cancers-19 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-19 option E, which supplied finding most strongly supports or refutes Lambert-Eaton syndrome producing periosteal new bone?

      It does not explain clubbing and radiographic periosteal bone formation. Thus, in lung-cancers-19 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Hypertrophic osteoarthropathy is a paraneoplastic pattern, not automatic evidence of bone metastases.

Case sources: ^{[1] [23]}

1. A. Small cell lung carcinoma (Why this does not fit)

   Small cell carcinoma arises as a pulmonary neuroendocrine carcinoma and often has a central mass. The supplied biopsy establishes malignant mesothelial differentiation in a pleural process instead.

   Reasoning steps for option A

   1. What tissue lineage characterizes small cell lung carcinoma? Apply that prediction to lung-cancers-20, option A: Small cell lung carcinoma.

      Small cell carcinoma arises as a pulmonary neuroendocrine carcinoma and often has a central mass. For lung-cancers-20 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-20 option A, which supplied finding most strongly supports or refutes Small cell lung carcinoma?

      The supplied biopsy establishes malignant mesothelial differentiation in a pleural process instead. Thus, in lung-cancers-20 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Typical bronchial carcinoid (Why this does not fit)

   Typical carcinoid is a well-differentiated neuroendocrine tumor, often presenting with endobronchial obstruction. It does not match a malignant mesothelial biopsy and diffuse pleural encasement.

   Reasoning steps for option B

   1. What tissue lineage characterizes typical bronchial carcinoid? Apply that prediction to lung-cancers-20, option B: Typical bronchial carcinoid.

      Typical carcinoid is a well-differentiated neuroendocrine tumor, often presenting with endobronchial obstruction. For lung-cancers-20 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-20 option B, which supplied finding most strongly supports or refutes Typical bronchial carcinoid?

      It does not match a malignant mesothelial biopsy and diffuse pleural encasement. Thus, in lung-cancers-20 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Pulmonary adenocarcinoma established solely by asbestos exposure (Why this does not fit)

   Asbestos increases lung carcinoma risk, so adenocarcinoma is possible in an exposed person. Exposure alone does not override the specifically mesothelial biopsy and pleural distribution.

   Reasoning steps for option C

   1. Can asbestos increase the risk of pulmonary carcinoma as well as mesothelioma? Apply that prediction to lung-cancers-20, option C: Pulmonary adenocarcinoma established solely by asbestos exposure.

      Asbestos increases lung carcinoma risk, so adenocarcinoma is possible in an exposed person. For lung-cancers-20 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-20 option C, which supplied finding most strongly supports or refutes Pulmonary adenocarcinoma established solely by asbestos exposure?

      Exposure alone does not override the specifically mesothelial biopsy and pleural distribution. Thus, in lung-cancers-20 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Benign asbestos-related pleural plaque (Why this does not fit)

   Asbestos exposure can cause benign pleural plaques. A biopsy-proven malignant mesothelial tumor cannot be reclassified as a benign plaque on the basis of the same exposure history.

   Reasoning steps for option D

   1. Can asbestos exposure produce benign pleural changes? Apply that prediction to lung-cancers-20, option D: Benign asbestos-related pleural plaque.

      Asbestos exposure can cause benign pleural plaques. For lung-cancers-20 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-20 option D, which supplied finding most strongly supports or refutes Benign asbestos-related pleural plaque?

      A biopsy-proven malignant mesothelial tumor cannot be reclassified as a benign plaque on the basis of the same exposure history. Thus, in lung-cancers-20 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Pleural mesothelioma (Best answer)

   A long-latency asbestos exposure with pleural encasement and malignant mesothelial tissue fits pleural mesothelioma. It is a pleural malignancy distinct from bronchial epithelial lung carcinoma.

   Reasoning steps for option E

   1. Which tissue of origin fits malignant mesothelioma? Apply that prediction to lung-cancers-20, option E: Pleural mesothelioma.

      A long-latency asbestos exposure with pleural encasement and malignant mesothelial tissue fits pleural mesothelioma. For lung-cancers-20 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-20 option E, which supplied finding most strongly supports or refutes Pleural mesothelioma?

      It is a pleural malignancy distinct from bronchial epithelial lung carcinoma. Thus, in lung-cancers-20 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Asbestos can cause both lung carcinoma and mesothelioma; the tissue of origin distinguishes them.

Case sources: ^[11]

1. A. Osimertinib alone as definitive initial treatment (Why this does not fit)

   The sensitizing EGFR alteration creates systemic-treatment options in defined settings. It does not replace potentially curative local treatment of an operable node-negative localized tumor.

   Reasoning steps for option A

   1. What role can a sensitizing EGFR alteration have in systemic treatment? Apply that prediction to lung-cancers-21, option A: Osimertinib alone as definitive initial treatment.

      The sensitizing EGFR alteration creates systemic-treatment options in defined settings. For lung-cancers-21 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-21 option A, which supplied finding most strongly supports or refutes Osimertinib alone as definitive initial treatment?

      It does not replace potentially curative local treatment of an operable node-negative localized tumor. Thus, in lung-cancers-21 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Resection with nodal assessment and stage-appropriate postoperative planning (Best answer)

   Operable localized NSCLC is generally evaluated for curative resection with appropriate nodal assessment. The final stage and biomarkers then guide whether additional systemic treatment is indicated.

   Reasoning steps for option B

   1. What is the usual curative-intent approach to an operable localized NSCLC? Apply that prediction to lung-cancers-21, option B: Resection with nodal assessment and stage-appropriate postoperative planning.

      Operable localized NSCLC is generally evaluated for curative resection with appropriate nodal assessment. For lung-cancers-21 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-21 option B, which supplied finding most strongly supports or refutes Resection with nodal assessment and stage-appropriate postoperative planning?

      The final stage and biomarkers then guide whether additional systemic treatment is indicated. Thus, in lung-cancers-21 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Platinum-pemetrexed-pembrolizumab alone (Why this does not fit)

   This is an important systemic approach for appropriately selected advanced nonsquamous disease. The supplied tumor is localized and operable, and its EGFR alteration also changes the systemic-treatment discussion.

   Reasoning steps for option C

   1. Which disease category usually receives this systemic-only strategy? Apply that prediction to lung-cancers-21, option C: Platinum-pemetrexed-pembrolizumab alone.

      This is an important systemic approach for appropriately selected advanced nonsquamous disease. For lung-cancers-21 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-21 option C, which supplied finding most strongly supports or refutes Platinum-pemetrexed-pembrolizumab alone?

      The supplied tumor is localized and operable, and its EGFR alteration also changes the systemic-treatment discussion. Thus, in lung-cancers-21 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Definitive concurrent platinum chemoradiation (Why this does not fit)

   Concurrent chemoradiation is used for suitable unresectable regional disease. The supplied node-negative localized tumor is operable, so that regional-disease strategy is not the best initial choice.

   Reasoning steps for option D

   1. Which regional setting commonly uses definitive concurrent chemoradiation? Apply that prediction to lung-cancers-21, option D: Definitive concurrent platinum chemoradiation.

      Concurrent chemoradiation is used for suitable unresectable regional disease. For lung-cancers-21 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-21 option D, which supplied finding most strongly supports or refutes Definitive concurrent platinum chemoradiation?

      The supplied node-negative localized tumor is operable, so that regional-disease strategy is not the best initial choice. Thus, in lung-cancers-21 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Serial CT surveillance without cancer-directed treatment (Why this does not fit)

   Surveillance can be appropriate for selected indeterminate nodules or patients for whom treatment is not appropriate. Here the lesion is confirmed adenocarcinoma and the patient is eligible for potentially curative treatment.

   Reasoning steps for option E

   1. When can surveillance rather than cancer treatment be reasonable? Apply that prediction to lung-cancers-21, option E: Serial CT surveillance without cancer-directed treatment.

      Surveillance can be appropriate for selected indeterminate nodules or patients for whom treatment is not appropriate. For lung-cancers-21 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-21 option E, which supplied finding most strongly supports or refutes Serial CT surveillance without cancer-directed treatment?

      Here the lesion is confirmed adenocarcinoma and the patient is eligible for potentially curative treatment. Thus, in lung-cancers-21 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Molecular results guide treatment within a stage; they do not substitute for staging or erase a curative local option.

Case sources: ^{[1] [4]}

1. A. Serial CT surveillance without local treatment (Why this does not fit)

   Surveillance can be appropriate for some indeterminate nodules or when treatment is unsuitable. This patient has confirmed localized cancer, wants active curative treatment, and has a feasible nonsurgical local option.

   Reasoning steps for option A

   1. When can surveillance be reasonable for a pulmonary lesion? Apply that prediction to lung-cancers-22, option A: Serial CT surveillance without local treatment.

      Surveillance can be appropriate for some indeterminate nodules or when treatment is unsuitable. For lung-cancers-22 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-22 option A, which supplied finding most strongly supports or refutes Serial CT surveillance without local treatment?

      This patient has confirmed localized cancer, wants active curative treatment, and has a feasible nonsurgical local option. Thus, in lung-cancers-22 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Platinum-based systemic chemotherapy alone (Why this does not fit)

   Systemic chemotherapy is central to many advanced or multimodal treatment plans. It does not replace an appropriate ablative local treatment for this isolated early-stage tumor.

   Reasoning steps for option B

   1. What role can chemotherapy have in advanced or multimodal care? Apply that prediction to lung-cancers-22, option B: Platinum-based systemic chemotherapy alone.

      Systemic chemotherapy is central to many advanced or multimodal treatment plans. For lung-cancers-22 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-22 option B, which supplied finding most strongly supports or refutes Platinum-based systemic chemotherapy alone?

      It does not replace an appropriate ablative local treatment for this isolated early-stage tumor. Thus, in lung-cancers-22 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Definitive concurrent chemoradiation (Why this does not fit)

   Concurrent treatment is commonly used for suitable unresectable regional NSCLC. This small node-negative localized tumor does not require that regional-disease strategy, and the patient has limited pulmonary reserve.

   Reasoning steps for option C

   1. Which extent of NSCLC commonly receives concurrent chemoradiation? Apply that prediction to lung-cancers-22, option C: Definitive concurrent chemoradiation.

      Concurrent treatment is commonly used for suitable unresectable regional NSCLC. For lung-cancers-22 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-22 option C, which supplied finding most strongly supports or refutes Definitive concurrent chemoradiation?

      This small node-negative localized tumor does not require that regional-disease strategy, and the patient has limited pulmonary reserve. Thus, in lung-cancers-22 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Stereotactic body radiation to the localized lung tumor (Best answer)

   SBRT is a curative-intent option for selected medically inoperable early-stage NSCLC. The combination of localized disease, unsafe surgery, and technical suitability supports it here.

   Reasoning steps for option D

   1. What local treatment can be used for medically inoperable early NSCLC? Apply that prediction to lung-cancers-22, option D: Stereotactic body radiation to the localized lung tumor.

      SBRT is a curative-intent option for selected medically inoperable early-stage NSCLC. For lung-cancers-22 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-22 option D, which supplied finding most strongly supports or refutes Stereotactic body radiation to the localized lung tumor?

      The combination of localized disease, unsafe surgery, and technical suitability supports it here. Thus, in lung-cancers-22 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Anatomical segmentectomy under general anesthesia (Why this does not fit)

   Limited resection may be considered for selected small tumors in an operable patient. The multidisciplinary assessment here states that resection is medically unsafe, so smaller tumor size does not eliminate the operative risk.

   Reasoning steps for option E

   1. Which patients may be considered for a limited lung resection? Apply that prediction to lung-cancers-22, option E: Anatomical segmentectomy under general anesthesia.

      Limited resection may be considered for selected small tumors in an operable patient. For lung-cancers-22 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-22 option E, which supplied finding most strongly supports or refutes Anatomical segmentectomy under general anesthesia?

      The multidisciplinary assessment here states that resection is medically unsafe, so smaller tumor size does not eliminate the operative risk. Thus, in lung-cancers-22 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Separate operability from disease extent: medically inoperable localized NSCLC may still have a curative-intent radiation option.

Case sources: ^[1]

1. A. Osimertinib (Why this does not fit)

   Osimertinib is used in defined EGFR-mutated NSCLC settings, not because a tumor has small cell morphology. No qualifying NSCLC EGFR indication is supplied.

   Reasoning steps for option A

   1. Which tumor and biomarker settings are relevant to osimertinib? Apply that prediction to lung-cancers-23, option A: Osimertinib.

      Osimertinib is used in defined EGFR-mutated NSCLC settings, not because a tumor has small cell morphology. For lung-cancers-23 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-23 option A, which supplied finding most strongly supports or refutes Osimertinib?

      No qualifying NSCLC EGFR indication is supplied. Thus, in lung-cancers-23 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Sotorasib (Why this does not fit)

   Sotorasib targets a specific KRAS variant in defined NSCLC settings. It is not a general consolidation treatment for limited-stage SCLC after chemoradiation.

   Reasoning steps for option B

   1. Which exact molecular variant is targeted by sotorasib? Apply that prediction to lung-cancers-23, option B: Sotorasib.

      Sotorasib targets a specific KRAS variant in defined NSCLC settings. For lung-cancers-23 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-23 option B, which supplied finding most strongly supports or refutes Sotorasib?

      It is not a general consolidation treatment for limited-stage SCLC after chemoradiation. Thus, in lung-cancers-23 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Durvalumab (Best answer)

   Durvalumab has a specific indication for adults with limited-stage SCLC whose disease has not progressed after concurrent platinum-based chemoradiation. The supplied treatment sequence and response satisfy the relevant setting.

   Reasoning steps for option C

   1. What preceding treatment and response match the limited-stage durvalumab indication? Apply that prediction to lung-cancers-23, option C: Durvalumab.

      Durvalumab has a specific indication for adults with limited-stage SCLC whose disease has not progressed after concurrent platinum-based chemoradiation. For lung-cancers-23 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-23 option C, which supplied finding most strongly supports or refutes Durvalumab?

      The supplied treatment sequence and response satisfy the relevant setting. Thus, in lung-cancers-23 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Lurbinectedin plus atezolizumab (Why this does not fit)

   That maintenance indication follows nonprogressing atezolizumab-carboplatin-etoposide induction for extensive-stage SCLC. It is not the same setting as limited-stage concurrent chemoradiation.

   Reasoning steps for option D

   1. What induction setting precedes lurbinectedin-atezolizumab maintenance? Apply that prediction to lung-cancers-23, option D: Lurbinectedin plus atezolizumab.

      That maintenance indication follows nonprogressing atezolizumab-carboplatin-etoposide induction for extensive-stage SCLC. For lung-cancers-23 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-23 option D, which supplied finding most strongly supports or refutes Lurbinectedin plus atezolizumab?

      It is not the same setting as limited-stage concurrent chemoradiation. Thus, in lung-cancers-23 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Tarlatamab (Why this does not fit)

   The cited tarlatamab indication concerns extensive-stage SCLC progressing on or after platinum therapy. This patient has limited-stage disease without progression, so that eligibility condition is absent.

   Reasoning steps for option E

   1. What disease course is required by the cited tarlatamab indication? Apply that prediction to lung-cancers-23, option E: Tarlatamab.

      The cited tarlatamab indication concerns extensive-stage SCLC progressing on or after platinum therapy. For lung-cancers-23 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-23 option E, which supplied finding most strongly supports or refutes Tarlatamab?

      This patient has limited-stage disease without progression, so that eligibility condition is absent. Thus, in lung-cancers-23 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Treatment sequence matters: durvalumab after nonprogressing concurrent chemoradiation is a limited-stage SCLC option.

Case sources: ^{[14] [18] [19]}

1. A. Primary resection followed by adjuvant platinum-etoposide (Why this does not fit)

   A surgical approach can be appropriate in a narrow carefully staged early node-negative SCLC setting. Documented liver and brain metastases place this patient outside that localized exception.

   Reasoning steps for option A

   1. Which SCLC patients can enter the narrow surgical pathway? Apply that prediction to lung-cancers-24, option A: Primary resection followed by adjuvant platinum-etoposide.

      A surgical approach can be appropriate in a narrow carefully staged early node-negative SCLC setting. For lung-cancers-24 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-24 option A, which supplied finding most strongly supports or refutes Primary resection followed by adjuvant platinum-etoposide?

      Documented liver and brain metastases place this patient outside that localized exception. Thus, in lung-cancers-24 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Concurrent thoracic radiation and platinum-etoposide as the complete initial strategy (Why this does not fit)

   Concurrent thoracic chemoradiation is a standard limited-stage approach. The supplied distant metastases require an extensive-stage systemic strategy, while site-specific radiation is planned separately.

   Reasoning steps for option B

   1. Which SCLC category commonly receives concurrent thoracic chemoradiation? Apply that prediction to lung-cancers-24, option B: Concurrent thoracic radiation and platinum-etoposide as the complete initial strategy.

      Concurrent thoracic chemoradiation is a standard limited-stage approach. For lung-cancers-24 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-24 option B, which supplied finding most strongly supports or refutes Concurrent thoracic radiation and platinum-etoposide as the complete initial strategy?

      The supplied distant metastases require an extensive-stage systemic strategy, while site-specific radiation is planned separately. Thus, in lung-cancers-24 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Carboplatin-pemetrexed-pembrolizumab (Why this does not fit)

   That combination fits selected advanced nonsquamous NSCLC. The tissue here is small cell carcinoma, which uses a different chemotherapy backbone.

   Reasoning steps for option C

   1. Which histology commonly uses carboplatin-pemetrexed-pembrolizumab? Apply that prediction to lung-cancers-24, option C: Carboplatin-pemetrexed-pembrolizumab.

      That combination fits selected advanced nonsquamous NSCLC. For lung-cancers-24 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-24 option C, which supplied finding most strongly supports or refutes Carboplatin-pemetrexed-pembrolizumab?

      The tissue here is small cell carcinoma, which uses a different chemotherapy backbone. Thus, in lung-cancers-24 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Platinum-etoposide without immunotherapy (Why this does not fit)

   Platinum-etoposide alone can be considered when immunotherapy is unsuitable. The patient is eligible for immunotherapy, making addition of a suitable PD-L1 inhibitor the better supplied first-line strategy.

   Reasoning steps for option D

   1. When might platinum-etoposide without immunotherapy be considered? Apply that prediction to lung-cancers-24, option D: Platinum-etoposide without immunotherapy.

      Platinum-etoposide alone can be considered when immunotherapy is unsuitable. For lung-cancers-24 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-24 option D, which supplied finding most strongly supports or refutes Platinum-etoposide without immunotherapy?

      The patient is eligible for immunotherapy, making addition of a suitable PD-L1 inhibitor the better supplied first-line strategy. Thus, in lung-cancers-24 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Platinum-etoposide with atezolizumab or durvalumab (Best answer)

   Liver and brain metastases establish extensive-stage SCLC. Platinum-etoposide plus an appropriate PD-L1 inhibitor addresses systemic disease, with local treatments considered separately for particular sites.

   Reasoning steps for option E

   1. Which systemic backbone fits extensive-stage SCLC in an immunotherapy-eligible patient? Apply that prediction to lung-cancers-24, option E: Platinum-etoposide with atezolizumab or durvalumab.

      Liver and brain metastases establish extensive-stage SCLC. For lung-cancers-24 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-24 option E, which supplied finding most strongly supports or refutes Platinum-etoposide with atezolizumab or durvalumab?

      Platinum-etoposide plus an appropriate PD-L1 inhibitor addresses systemic disease, with local treatments considered separately for particular sites. Thus, in lung-cancers-24 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Extensive-stage SCLC requires a systemic strategy; radiation to selected sites does not replace that strategy.

Case sources: ^{[2] [12]}

1. A. Appropriate adjuvant platinum-etoposide chemotherapy (Best answer)

   Surgery can be part of multimodal care for carefully staged early node-negative SCLC. Negative margins and nodes do not eliminate the risk of microscopic systemic disease, so adjuvant chemotherapy remains important.

   Reasoning steps for option A

   1. Can carefully staged early node-negative SCLC ever receive surgery? Apply that prediction to lung-cancers-25, option A: Appropriate adjuvant platinum-etoposide chemotherapy.

      Surgery can be part of multimodal care for carefully staged early node-negative SCLC. For lung-cancers-25 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-25 option A, which supplied finding most strongly supports or refutes Appropriate adjuvant platinum-etoposide chemotherapy?

      Negative margins and nodes do not eliminate the risk of microscopic systemic disease, so adjuvant chemotherapy remains important. Thus, in lung-cancers-25 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Surveillance alone after complete resection (Why this does not fit)

   Surveillance is part of follow-up, but an R0 resection describes local completeness rather than proof that systemic microscopic disease is absent. It does not generally replace adjuvant chemotherapy in this SCLC setting.

   Reasoning steps for option B

   1. What does an R0 resection prove and what does it not prove? Apply that prediction to lung-cancers-25, option B: Surveillance alone after complete resection.

      Surveillance is part of follow-up, but an R0 resection describes local completeness rather than proof that systemic microscopic disease is absent. For lung-cancers-25 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-25 option B, which supplied finding most strongly supports or refutes Surveillance alone after complete resection?

      It does not generally replace adjuvant chemotherapy in this SCLC setting. Thus, in lung-cancers-25 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Adjuvant pemetrexed-based treatment selected as for nonsquamous NSCLC (Why this does not fit)

   Pemetrexed is used in nonsquamous NSCLC treatment settings. The established small cell histology instead supports an appropriate SCLC chemotherapy backbone.

   Reasoning steps for option C

   1. Which histology uses pemetrexed-containing regimens? Apply that prediction to lung-cancers-25, option C: Adjuvant pemetrexed-based treatment selected as for nonsquamous NSCLC.

      Pemetrexed is used in nonsquamous NSCLC treatment settings. For lung-cancers-25 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-25 option C, which supplied finding most strongly supports or refutes Adjuvant pemetrexed-based treatment selected as for nonsquamous NSCLC?

      The established small cell histology instead supports an appropriate SCLC chemotherapy backbone. Thus, in lung-cancers-25 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Postoperative thoracic radiation alone (Why this does not fit)

   Postoperative radiation may be considered for particular nodal or margin findings. The supplied nodes and margins are negative, and thoracic radiation alone does not replace the systemic chemotherapy component.

   Reasoning steps for option D

   1. What findings may influence a postoperative radiation decision? Apply that prediction to lung-cancers-25, option D: Postoperative thoracic radiation alone.

      Postoperative radiation may be considered for particular nodal or margin findings. For lung-cancers-25 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-25 option D, which supplied finding most strongly supports or refutes Postoperative thoracic radiation alone?

      The supplied nodes and margins are negative, and thoracic radiation alone does not replace the systemic chemotherapy component. Thus, in lung-cancers-25 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Durvalumab alone under the post-chemoradiation indication (Why this does not fit)

   Durvalumab has a specific limited-stage indication after nonprogressing concurrent platinum chemoradiation. Surgery alone is not that preceding treatment sequence, and durvalumab alone does not replace adjuvant chemotherapy here.

   Reasoning steps for option E

   1. Which preceding treatment is required for post-chemoradiation durvalumab? Apply that prediction to lung-cancers-25, option E: Durvalumab alone under the post-chemoradiation indication.

      Durvalumab has a specific limited-stage indication after nonprogressing concurrent platinum chemoradiation. For lung-cancers-25 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-25 option E, which supplied finding most strongly supports or refutes Durvalumab alone under the post-chemoradiation indication?

      Surgery alone is not that preceding treatment sequence, and durvalumab alone does not replace adjuvant chemotherapy here. Thus, in lung-cancers-25 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Early node-negative SCLC has a surgical exception, but surgery is part of multimodal treatment rather than a substitute for chemotherapy.

Case sources: ^[12]

1. A. Alectinib (Why this does not fit)

   Alectinib targets ALK-positive NSCLC. The supplied actionable alteration is an EGFR exon 19 deletion, not an ALK rearrangement.

   Reasoning steps for option A

   1. What alteration does alectinib target? Apply that prediction to lung-cancers-26, option A: Alectinib.

      Alectinib targets ALK-positive NSCLC. For lung-cancers-26 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-26 option A, which supplied finding most strongly supports or refutes Alectinib?

      The supplied actionable alteration is an EGFR exon 19 deletion, not an ALK rearrangement. Thus, in lung-cancers-26 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Sotorasib (Why this does not fit)

   Sotorasib targets KRAS G12C in defined advanced NSCLC settings. Neither the required KRAS variant nor its usual previously treated metastatic setting is supplied.

   Reasoning steps for option B

   1. What alteration and treatment setting fit sotorasib? Apply that prediction to lung-cancers-26, option B: Sotorasib.

      Sotorasib targets KRAS G12C in defined advanced NSCLC settings. For lung-cancers-26 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-26 option B, which supplied finding most strongly supports or refutes Sotorasib?

      Neither the required KRAS variant nor its usual previously treated metastatic setting is supplied. Thus, in lung-cancers-26 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Pembrolizumab monotherapy (Why this does not fit)

   Pembrolizumab alone is used in selected PD-L1-positive NSCLC settings without a competing actionable first-line driver. It does not match this specific EGFR-mutated post-chemoradiation indication.

   Reasoning steps for option C

   1. Where can pembrolizumab monotherapy fit in NSCLC treatment? Apply that prediction to lung-cancers-26, option C: Pembrolizumab monotherapy.

      Pembrolizumab alone is used in selected PD-L1-positive NSCLC settings without a competing actionable first-line driver. For lung-cancers-26 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-26 option C, which supplied finding most strongly supports or refutes Pembrolizumab monotherapy?

      It does not match this specific EGFR-mutated post-chemoradiation indication. Thus, in lung-cancers-26 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Osimertinib (Best answer)

   Osimertinib has an indication for unresectable stage III NSCLC with an EGFR exon 19 deletion or exon 21 L858R that has not progressed after concurrent or sequential platinum-based chemoradiation. The sequential schedule therefore does not exclude this biomarker-defined option.

   Reasoning steps for option D

   1. Which EGFR variants and chemoradiation sequences match this osimertinib indication? Apply that prediction to lung-cancers-26, option D: Osimertinib.

      Osimertinib has an indication for unresectable stage III NSCLC with an EGFR exon 19 deletion or exon 21 L858R that has not progressed after concurrent or sequential platinum-based chemoradiation. For lung-cancers-26 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-26 option D, which supplied finding most strongly supports or refutes Osimertinib?

      The sequential schedule therefore does not exclude this biomarker-defined option. Thus, in lung-cancers-26 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Durvalumab (Why this does not fit)

   Durvalumab is an established consolidation option for suitable patients after definitive chemoradiation. That does not make consolidation biomarker-independent; the supplied EGFR alteration and sequence specifically match osimertinib's indication.

   Reasoning steps for option E

   1. In what broad NSCLC setting can consolidation durvalumab be used? Apply that prediction to lung-cancers-26, option E: Durvalumab.

      Durvalumab is an established consolidation option for suitable patients after definitive chemoradiation. For lung-cancers-26 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-26 option E, which supplied finding most strongly supports or refutes Durvalumab?

      That does not make consolidation biomarker-independent; the supplied EGFR alteration and sequence specifically match osimertinib's indication. Thus, in lung-cancers-26 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: For unresectable stage III NSCLC, match consolidation to the molecular result and the actual preceding treatment sequence.

Case sources: ^{[1] [15]}

1. A. Pembrolizumab monotherapy (Why this does not fit)

   Pembrolizumab monotherapy selection depends on the appropriate PD-L1-positive setting and other factors. A value below 1% does not support this monotherapy rationale, although it does not exclude benefit from a combination.

   Reasoning steps for option A

   1. Does PD-L1 below 1% support the supplied monotherapy rationale? Apply that prediction to lung-cancers-28, option A: Pembrolizumab monotherapy.

      Pembrolizumab monotherapy selection depends on the appropriate PD-L1-positive setting and other factors. For lung-cancers-28 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-28 option A, which supplied finding most strongly supports or refutes Pembrolizumab monotherapy?

      A value below 1% does not support this monotherapy rationale, although it does not exclude benefit from a combination. Thus, in lung-cancers-28 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Osimertinib (Why this does not fit)

   Nonsquamous histology prompts molecular evaluation but does not itself establish an EGFR target. The supplied profiling has found no actionable first-line driver.

   Reasoning steps for option B

   1. Does nonsquamous morphology itself establish an EGFR target? Apply that prediction to lung-cancers-28, option B: Osimertinib.

      Nonsquamous histology prompts molecular evaluation but does not itself establish an EGFR target. For lung-cancers-28 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-28 option B, which supplied finding most strongly supports or refutes Osimertinib?

      The supplied profiling has found no actionable first-line driver. Thus, in lung-cancers-28 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Platinum-etoposide (Why this does not fit)

   Platinum-etoposide is commonly used for small cell carcinoma and some other defined settings. It is not the usual nonsquamous metastatic NSCLC chemotherapy backbone described here.

   Reasoning steps for option C

   1. Which lung cancer family commonly receives platinum-etoposide? Apply that prediction to lung-cancers-28, option C: Platinum-etoposide.

      Platinum-etoposide is commonly used for small cell carcinoma and some other defined settings. For lung-cancers-28 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-28 option C, which supplied finding most strongly supports or refutes Platinum-etoposide?

      It is not the usual nonsquamous metastatic NSCLC chemotherapy backbone described here. Thus, in lung-cancers-28 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Platinum-pemetrexed alone (Why this does not fit)

   Platinum-pemetrexed is a plausible chemotherapy component for nonsquamous NSCLC. The mistake is treating low PD-L1 as an absolute exclusion of immunotherapy when a chemotherapy-immunotherapy combination is suitable.

   Reasoning steps for option D

   1. Does low PD-L1 categorically exclude combination immunotherapy? Apply that prediction to lung-cancers-28, option D: Platinum-pemetrexed alone.

      Platinum-pemetrexed is a plausible chemotherapy component for nonsquamous NSCLC. For lung-cancers-28 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-28 option D, which supplied finding most strongly supports or refutes Platinum-pemetrexed alone?

      The mistake is treating low PD-L1 as an absolute exclusion of immunotherapy when a chemotherapy-immunotherapy combination is suitable. Thus, in lung-cancers-28 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Platinum-pemetrexed plus pembrolizumab (Best answer)

   Nonsquamous histology supports a pemetrexed-containing backbone, while the absence of an actionable first-line driver permits an immunotherapy-based approach. Low PD-L1 does not preclude an appropriate chemotherapy-immunotherapy combination.

   Reasoning steps for option E

   1. How do nonsquamous histology and absence of a first-line driver affect regimen selection? Apply that prediction to lung-cancers-28, option E: Platinum-pemetrexed plus pembrolizumab.

      Nonsquamous histology supports a pemetrexed-containing backbone, while the absence of an actionable first-line driver permits an immunotherapy-based approach. For lung-cancers-28 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-28 option E, which supplied finding most strongly supports or refutes Platinum-pemetrexed plus pembrolizumab?

      Low PD-L1 does not preclude an appropriate chemotherapy-immunotherapy combination. Thus, in lung-cancers-28 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Low PD-L1 and driver-negative disease are not equivalent to an instruction to omit immunotherapy from every regimen.

Case sources: ^[1]

1. A. Sotorasib (Best answer)

   Sotorasib targets KRAS G12C and has an indication in previously treated advanced NSCLC. The exact G12C variant and prior systemic treatment are both necessary parts of the match.

   Reasoning steps for option A

   1. Which precise KRAS alteration does sotorasib target? Apply that prediction to lung-cancers-29, option A: Sotorasib.

      Sotorasib targets KRAS G12C and has an indication in previously treated advanced NSCLC. For lung-cancers-29 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-29 option A, which supplied finding most strongly supports or refutes Sotorasib?

      The exact G12C variant and prior systemic treatment are both necessary parts of the match. Thus, in lung-cancers-29 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Osimertinib (Why this does not fit)

   Osimertinib targets defined EGFR-mutated NSCLC settings. No sensitizing EGFR alteration is present, so it does not match the supplied molecular driver.

   Reasoning steps for option B

   1. Which molecular family is relevant to osimertinib? Apply that prediction to lung-cancers-29, option B: Osimertinib.

      Osimertinib targets defined EGFR-mutated NSCLC settings. For lung-cancers-29 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-29 option B, which supplied finding most strongly supports or refutes Osimertinib?

      No sensitizing EGFR alteration is present, so it does not match the supplied molecular driver. Thus, in lung-cancers-29 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. Alectinib (Why this does not fit)

   Alectinib targets ALK-positive disease. The tumor lacks an ALK rearrangement and instead carries the specified KRAS G12C alteration.

   Reasoning steps for option C

   1. Which rearrangement is relevant to alectinib? Apply that prediction to lung-cancers-29, option C: Alectinib.

      Alectinib targets ALK-positive disease. For lung-cancers-29 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-29 option C, which supplied finding most strongly supports or refutes Alectinib?

      The tumor lacks an ALK rearrangement and instead carries the specified KRAS G12C alteration. Thus, in lung-cancers-29 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. Capmatinib (Why this does not fit)

   Capmatinib is used for NSCLC with an alteration causing MET exon 14 skipping. A KRAS G12C result does not establish that distinct target.

   Reasoning steps for option D

   1. Which MET alteration is relevant to capmatinib? Apply that prediction to lung-cancers-29, option D: Capmatinib.

      Capmatinib is used for NSCLC with an alteration causing MET exon 14 skipping. For lung-cancers-29 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-29 option D, which supplied finding most strongly supports or refutes Capmatinib?

      A KRAS G12C result does not establish that distinct target. Thus, in lung-cancers-29 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Selpercatinib (Why this does not fit)

   Selpercatinib targets RET-altered disease in defined settings. The supplied KRAS variant is not a RET fusion and does not justify substituting one molecularly matched drug for another.

   Reasoning steps for option E

   1. Which molecular family is relevant to selpercatinib? Apply that prediction to lung-cancers-29, option E: Selpercatinib.

      Selpercatinib targets RET-altered disease in defined settings. For lung-cancers-29 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-29 option E, which supplied finding most strongly supports or refutes Selpercatinib?

      The supplied KRAS variant is not a RET fusion and does not justify substituting one molecularly matched drug for another. Thus, in lung-cancers-29 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: KRAS G12C is actionable in a defined setting; the variant and line of therapy matter, not merely the word KRAS.

Case sources: ^{[1] [17]}

1. A. The effusion changes only the primary tumor's T category (Why this does not fit)

   Local primary-tumor features contribute to T classification, but a proven malignant pleural effusion has a metastatic classification. It is not merely a change in primary diameter or local extent.

   Reasoning steps for option A

   1. Does malignant pleural fluid belong solely to primary-tumor size assessment? Apply that prediction to lung-cancers-30, option A: The effusion changes only the primary tumor's T category.

      Local primary-tumor features contribute to T classification, but a proven malignant pleural effusion has a metastatic classification. For lung-cancers-30 option A, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-30 option A, which supplied finding most strongly supports or refutes The effusion changes only the primary tumor's T category?

      It is not merely a change in primary diameter or local extent. Thus, in lung-cancers-30 option A, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

2. B. Negative mediastinal nodes keep the disease nonmetastatic despite malignant pleural fluid (Why this does not fit)

   Nodal status and metastatic spread are separate components. Negative mediastinal nodes do not negate cytologically established malignant pleural involvement.

   Reasoning steps for option B

   1. Are nodal and metastatic categories independent parts of staging? Apply that prediction to lung-cancers-30, option B: Negative mediastinal nodes keep the disease nonmetastatic despite malignant pleural fluid.

      Nodal status and metastatic spread are separate components. For lung-cancers-30 option B, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-30 option B, which supplied finding most strongly supports or refutes Negative mediastinal nodes keep the disease nonmetastatic despite malignant pleural fluid?

      Negative mediastinal nodes do not negate cytologically established malignant pleural involvement. Thus, in lung-cancers-30 option B, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

3. C. The malignant pleural effusion establishes M1a disease despite the small primary (Best answer)

   A confirmed malignant pleural effusion is classified as intrathoracic metastatic disease, M1a. Small tumor diameter and negative nodes do not erase that finding or justify a surgery-only plan.

   Reasoning steps for option C

   1. What staging category includes a proven malignant pleural effusion? Apply that prediction to lung-cancers-30, option C: The malignant pleural effusion establishes M1a disease despite the small primary.

      A confirmed malignant pleural effusion is classified as intrathoracic metastatic disease, M1a. For lung-cancers-30 option C, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-30 option C, which supplied finding most strongly supports or refutes The malignant pleural effusion establishes M1a disease despite the small primary?

      Small tumor diameter and negative nodes do not erase that finding or justify a surgery-only plan. Thus, in lung-cancers-30 option C, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

4. D. An ipsilateral malignant effusion is classified as N1 nodal disease (Why this does not fit)

   N1 describes specified ipsilateral intrapulmonary or hilar regional nodes. Malignant cells in pleural fluid are not a regional nodal category.

   Reasoning steps for option D

   1. Which anatomical structures are classified as N1 nodes? Apply that prediction to lung-cancers-30, option D: An ipsilateral malignant effusion is classified as N1 nodal disease.

      N1 describes specified ipsilateral intrapulmonary or hilar regional nodes. For lung-cancers-30 option D, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-30 option D, which supplied finding most strongly supports or refutes An ipsilateral malignant effusion is classified as N1 nodal disease?

      Malignant cells in pleural fluid are not a regional nodal category. Thus, in lung-cancers-30 option D, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

5. E. Metastatic classification requires an extrathoracic deposit (Why this does not fit)

   Some metastatic categories are intrathoracic. The malignant pleural effusion is sufficient for M1a even when no extrathoracic lesion is found.

   Reasoning steps for option E

   1. Must every metastatic deposit lie outside the thorax? Apply that prediction to lung-cancers-30, option E: Metastatic classification requires an extrathoracic deposit.

      Some metastatic categories are intrathoracic. For lung-cancers-30 option E, treat this as one mechanistic prediction and test it against the stem's tissue, anatomic, laboratory, and treatment clues.

   2. For lung-cancers-30 option E, which supplied finding most strongly supports or refutes Metastatic classification requires an extrathoracic deposit?

      The malignant pleural effusion is sufficient for M1a even when no extrathoracic lesion is found. Thus, in lung-cancers-30 option E, accept the choice only when its predicted pattern fits the full vignette rather than a single familiar association.

Takeaway: Stage is not determined by the largest-looking lesion: proven malignant pleural fluid establishes metastatic extent.

Case sources: ^[1]